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General Introduction 
Cholera Disease 
Vibrio cholerae is a gram-negative, curved rod-shaped bacterium that causes the severe 
diarrheal illness cholera. When a host ingests large quantities of fecal-contaminated water or 
raw shellfish colonized with V. cholerae, disease can occur within a short incubation period 
from as little as two hours to up to five days. Cholera is characterized by severe dehydration 
and shock caused by voluminous watery diarrhea, colloquially known as “rice-water stool” as its 
appearance is similar to water left over from washing rice.  Other symptoms include vomiting, 
leg cramps, and decreased skin turgor due to the dehydration (1, 2). Treatment includes oral 
rehydration solution (ORS) as specified by the World Health Organization (WHO) to contain 
strict amounts of various salts including sodium chloride, trisodium citrate dihydrate, and 
potassium chloride, as well as glucose (3).  For severe patients, additional IV fluids containing 
sodium and glucose are administered to relieve dehydration.  As cholera patients can lose up to 
one liter of water per hour in the early stages of the disease, ORS not only hydrates the patient, 
but also insures that cholera patients have their sodium levels replenished in the small intestine 
(4, 5). In addition, antibiotics also may be used conjointly to slightly shorten the disease 
symptom duration and reduce the period of time that there is bacterial shedding into the 
environment.  
Approximately 75% of people show no symptoms when infected with V. cholerae; 
however, these carriers can still shed bacteria for 7-14 days, albeit at lower amounts than a 
person showing symptoms. In addition, carriers can still infect other people (6, 7).  For the 
children or adults who develop symptoms, approximately 80% experience mild or moderate 
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symptoms, with the remaining 20% experiencing severe symptoms that include massive 
dehydration and diarrhea. Without treatment, survival is approximately 50% and death can 
occur within a few hours after the onset of diarrhea; however, with treatment survival is 
approximately 99% (8). 
 
Global Impact of Cholera 
Although scholars disagree on when the first instances of cholera occurred, there is 
historical evidence of a disease that resembles cholera dating back thousands of years in the 
Indian subcontinent. The origins of the word cholera likely come from the Greek words “chole,” 
meaning bile, and “rein,” meaning to flow, first used in Hippocrates writing around 400 BC. 
Written accounts of cholera also appear in Sanskrit around 500 BC (9). The first recorded 
pandemic of cholera occurred in 1817, as traders visited India and carried the disease with 
them, and since then a total of seven pandemics have occurred, with the most recent, seventh 
pandemic still ongoing (10).  As the world became more industrialized, cholera likely spread 
following trade and immigration routes, and first reached the United States in 1832 (11).  It was 
initially thought cholera spread through inhalation of a foul-smelling pollution known as 
miasma, but this myth was dispelled during the third pandemic that occurred in the 1850s (9).  
John Snow, a practicing physician in London, showed in 1854 that the source of a large and very 
deadly outbreak of cholera was a town water pump in the Soho region of London (12).  Once 
the pump was decommissioned, the epidemic ended in this region of London (12). Around this 
same time, Filippo Pacini isolated “comma-like” shaped bacteria from the intestinal lumens of 
deceased cholera patients and described these as both infectious and the causative agent of 
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the disease (13). However, his publication was written in Italian and was not widely 
disseminated. It was not until 1884, one year after Pacini’s death, that Robert Koch 
rediscovered V. cholerae from patients and publicized the information, therefore getting credit 
for many years as the initial discoverer of V. cholerae (13). 
In regards to recent cases of cholera, the WHO reported that the incidence of cholera 
had increased steadily from 2005-2012, and although the number of reported cases has 
decreased since then, it continues to be a concern (14). This is especially true in the developing 
world, where access to clean water and adequate sanitation is a problem.  In 2013, 129,064 
cases of cholera were officially reported to WHO, resulting in 2,102 deaths, but the number of 
cholera cases each year is actually estimated to be between 1.4-4.3 million cases with 28,000-
142,000 deaths worldwide (14, 15).  This large discrepancy between reported cases and 
estimated cases may in part be due to underreporting because of lack of consistency in case 
definitions, but also because of the negative political and economic implications on travel and 
trade resulting from a publicized cholera epidemic.   
Cholera is currently endemic in approximately 50 countries, mainly within Asia and 
Africa.  From the mid-1990s until 2010, the continent of Africa reported the greatest number of 
cases, but in 2010 an earthquake hit Haiti, resulting in a massive increase in cholera cases in the 
Americas (14). As a result of the earthquake, there was infrastructure breakdown and, within a 
month, a cholera outbreak occurred, spreading throughout the entire country and eventually to 
the Dominican Republic and Cuba. This ongoing outbreak has led to over 700,000 cases and 
over 8,000 deaths (2). 
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V. cholerae is classified based on the O antigen of its lipopolysaccharide, and despite the 
fact there are over 200 serogroups in the environment, all seven pandemics have been 
attributed to one serogroup, O1 (1, 8, 16). The O1 serogroup can be further divided into two 
biotypes: classical and El Tor. Historically, the classification difference has been based upon 
different phenotypes such as hemolysis, hemagglutination, phage lysis and polymyxin B 
resistance, but more recently, it has been shown that the two biotypes are genotypically 
different as well (17, 18). The classical biotype was the causative agent of the first six 
pandemics, while the El Tor biotype has caused the most current pandemic (8, 16). The classical 
biotype also causes a more severe disease, but El Tor is thought to survive better in the 
environment, although the reasons for this are not understood (16, 17). One additional 
serogroup, O139, emerged in 1992 and is the causative agent of more recent outbreaks (18-21). 
O139 is genetically very similar to O1 EL Tor biotype, suggesting horizontal gene transfer of the 
O antigen biosynthetic genes, which in turn, caused the conversion (18, 22, 23). As such, some 
refer to these outbreaks as an eighth pandemic (18). 
Even though cholera is a huge problem worldwide and much work has been done to 
make effective vaccines, there are no current vaccines that offer long-term or complete 
protection. Two oral cholera vaccines are available: the first is called Dukoral and is composed 
of killed whole cells in a mixture of the two biotypes of O1 V. cholerae, plus a recombinant B 
subunit of the cholera toxin (to be discussed later), and another called Shanchol that has both 
O1 and O139 serogroups. Dukoral is manufactured by SBL Vaccines in Sweden and prequalified 
and licensed in over 60 countries, but not the United States (24). Shanchol is manufactured by 
Shantha Biotec in India and in 2011 acquired WHO prequalification and was used in a 2012 pilot 
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study to look at feasibility, not efficacy, of mass vaccination in Haiti (25-27). Disappointingly, 
both of these vaccines need to be taken in multiple doses and have been shown only to be 
about 50-60% effective in the first year (28, 29).  Injectable vaccines of whole cells are no longer 
used.  Making an effective vaccine is currently a top priority as stated in the WHO Model List of 
Essential Medicines (30).  The Centers for Disease Control and Prevention (CDC) currently does 
not recommend receiving a cholera vaccination for travelers, and, as stated, neither vaccine is 
available in the United States. This is due to the fact that the vaccines only offer partial 
protection for a short period of time. 
 
V. cholerae Life Cycle 
V. cholerae is found predominantly in the aquatic environment as normal inhabitants of 
freshwater, coastal and brackish waters as either free-swimming bacteria or in association with 
marine organisms including shellfish, copepods, chironomid egg masses, and vertebrate fish 
(31-37).  Changes in weather that affect surface water temperature and therefore 
phytoplankton blooms have been correlated with cholera outbreaks (38, 39). In nature, humans 
are generally the only host of V. cholerae to get cholera disease, but a very high infectious dose 
of around 106-1011 bacteria is necessary to infect healthy individuals (17). In the environment, 
both motility and chemotaxis genes are expressed, which are also important at early time 
points after human ingestion. Expression of these genes allows the bacteria to pass through the 
host’s defenses such as the low pH of the stomach, bile from the duodenum, and the innate 
immune system (40, 41). Using its single polar flagellum, V. cholerae is able to traverse the 
stomach and enter the small intestine, where it is then able to pass into the protective mucus 
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layer of the intestine and colonize the surface of the epithelium in the intestinal crypts and villi 
surfaces (42-44). At this point, the bacteria downregulate motility genes and become immotile, 
while genes involved in virulence are upregulated (40, 41).  Colonization occurs for 
approximately 12-72 hours before symptoms occur (6). Once a person begins to shed the 
bacteria through either vomit or diarrhea, termed the “mucosal escape response”, V. cholerae 
is in a hyperinfectious state where the infectious dose can be as low as 10-100 bacteria needed 
to infect a new host (45-48). Gene expression is now reversed, such that there is 
downregulation of genes involved in virulence and upregulation of genes required for motility, 
as well as upregulated protease expression that allows detachment from the epithelium (49). 
The hyperinfectious state lasts for at least five hours, and seems to be an effective way that the 
bacteria can pass from person-to-person, particularly in heavily crowded areas such as a 
household, potentially causing an epidemic due to the rapid rate of infection (46, 47). Bacteria 
shed from humans have been shown to be in two forms: a more infectious biofilm-like form 
with small aggregates of bacteria and a planktonic form (47, 48, 50). 
When not in a human host, V. cholerae naturally lives in an aquatic environment. In 
aquatic environments, the bacteria live as either free-swimming planktonic cells or attached to 
various types of surfaces that can be living or non-living (31, 36, 37, 51-53). As part of the free-
swimming state, V. cholerae can persist in a condition traditionally known as viable but non-
culturable (54). In this state, the bacteria cannot be cultured on standard media but are still 
able to perform some metabolic processes such as protein synthesis and maintain membrane 
integrity (55). This state is thought to occur when the bacteria are not associated with chitin, 
and therefore are nutrient-deprived (55). The term “viable” has been questioned, as it is 
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unclear if the bacteria are actually alive in this state as they cannot be cultured, therefore a 
more conservative term of “active but non-culturable” (ABNC) has also been used (6). These 
bacteria can regain the ability to multiply when put into a human once again, or are grown in 
the presence of eukaryotic cells, and can be cultured after such exposures (56, 57).  
When not free-swimming or ABNC, V. cholerae can associate with marine organisms in a 
biofilm either on the organism, or on chitin (such as the shell of crustaceans) where chitin can 
then be used as a carbon and nitrogen source (58-60). In general, a biofilm is a micro-
community of bacteria that is attached to some surface and is composed of a matrix of DNA, 
proteins, and polysaccharides that holds the micro-community together. In V. cholerae, biofilm 
formation is mediated by the Vibrio polysaccharide (VPS) regulon, which encodes extracellular 
polysaccharide and leads to increased resistance to chlorine (61-63).  Bacteria found in 
association with a biofilm, as opposed to free-swimming bacteria, display hyperinfectivity and it 
has been postulated that this form is the most likely source of human infections (64-66).  
Potentially, this could be at least in part because bacteria associated with a biofilm have 
decreased acid susceptibility, which in turn allows the bacteria to better survive throughout the 
stomach (67). 
 
V. cholerae Pathogenesis Genes 
In order to initiate disease, and potentially cause a pandemic, production of two 
virulence factors is necessary: cholera toxin (CT) and toxin co-regulated pilus (TCP). These are 
acquired from the mobile genetic elements cholera toxin bacteriophage (CTXφ) and the Vibrio 
pathogenicity island (VPI), respectively. CTXφ is a filamentous bacteriophage with a 6.9 kb 
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single-stranded DNA genome and is found in all pandemic strain environmental isolates, but 
rarely found in non-O1/O139 environmental strains (16). CTXφ is separately inserted in each of 
the two V. cholerae chromosomes in the classical strain, but is found tandemly arranged on the 
larger chromosome of El Tor (68-71).  Uptake of this prophage is dependent on TCP as its 
receptor to enter V. cholerae cells and to convert nontoxigenic strains into toxigenic ones (72).  
As TCP is expressed in the intestine, this lysogenic conversion occurs inside the host (72). In 
addition to encoding the genes for CT, CTXφ also carries genes that encode the zona occludens 
toxin (Zot) and accessory enterotoxin (Ace); however, the role in pathogenesis of these 
additional toxins remains unclear (71, 73-75). VPI is 40 kb long, and, besides containing the 
genes required for TCP production, also encodes a number of other accessory virulence factors.  
Like the accessory toxins encoded by CTXφ , most of these accessory factors have poorly 
defined roles in pathogenesis (76, 77).  
 CT, the cause of the voluminous diarrhea in cholera, was first discovered to act as an 
enterotoxin by S.N. De in 1959, but it was not isolated until 1969 by Finkelstein and LoSpalluto 
(77-79). De discovered that cell-free supernatants for the classical biotype could cause fluid 
accumulation in rabbit ligated ileal loops in a similar manner to when V. cholerae cultures were 
injected in the loops (78). Since that initial discovery, much research has been conducted on CT.  
CT is an 84 kDa protein, part of the large family of bipartite A-B toxins consisting of five smaller 
subunits, collectively called the B subunit, responsible for binding the toxin to its target and one 
larger subunit, the A subunit, responsible for the toxin action (77, 80-82). The 6 subunit 
holotoxin is assembled in the periplasm, and then secreted by a type II secretion system (83). 
The B subunit pentamer binds to the receptor of cholera toxin, ganglioside GM1, found 
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associated in lipid rafts on the intestinal epithelial cell surfaces (81, 84-86).  This bound complex 
is endocytosed and then continues through retrograde transport to the endoplasmic reticulum 
(ER) (87-89). Once in the ER, the toxin is able to use the ER-associated protein degradation 
pathway to release the A1 subunit into the cytosol of the host (90, 91).  Inside the host cell, the 
A subunit dissociates from the B subunit, and it is then cleaved by host proteases into two 
fragments: A1 and A2. The A1 subunit contains the active site, while the disulfide bond-
attached A2 subunit functions as a tether to the B subunit pentamer (92).  The A1 subunit then 
ADP-ribosylates the Gsα subunit of adenylate cyclase causing adenylate cyclase to be locked in 
its GTP-bound active state (93).  This in turn causes an increased concentration of cAMP, 
leading to a rapid secretion of chloride ions from crypt cells and therefore decreased sodium 
uptake from the surrounding villus cells (94, 95).  This electrolyte imbalance causes an osmotic 
gradient which in turn causes massive secretion of water from the cells into the intestinal 
lumen (96, 97).  This fluid accumulation in the small intestine is the source of the profuse 
watery diarrhea associated with the disease. 
 TCP is the other major virulence factor produced by V. cholerae that is essential to cause 
cholera disease (76, 98). TCP is a type IV bundle-forming pilus that is expressed under the same 
conditions as CT, thus leading to the term “toxin co-regulated” (99-101).  The exact role of TCP 
in colonization is not yet defined, as it has not been shown to act as an adhesin for cell-bacteria 
interactions, but it has been shown to mediate microcolony formation on the surface of 
epithelial cells and therefore its required role may be for inter-bacterial interactions (99). 
Assembled TCP bundles are between 5-7nm in diameter and are composed of polymers of the 
first protein encoded by the tcp operon, TcpA (99). The 12 gene tcp operon is located on the VPI 
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(16).  In V. cholerae strains in which tcpA have been deleted, the bacteria are no longer able to 
colonize the small intestine, as shown in healthy human volunteer studies (98). TCP is also 
involved in the secretion of the colonization factor TcpF, but is not clear how this required 
factor is used for colonization (102). It is known that tcpJ is involved in the processing of TcpA 
during secretion by encoding a leader peptidase (103). Most of the tcp operon is either involved 
in or part of the actual pilus. 
  Other genes important for host colonization that are located on the VPI have also been 
identified, including acfABCD, aldA, tagA, and tcpI, but their roles are largely unknown (1, 104-
110). The acf genes make up the accessory colonization factor (ACF) and are required for 
enhanced intestinal colonization in mice, but the functions of the proteins are still largely 
unknown (108). AcfB and TcpI share homology with methyl-accepting chemotaxis proteins, and 
when mutated together cause decreased colonization in mice (106, 111, 112).  Decreased 
colonization does not occur when each gene is mutated individually, suggesting redundancy in 
the chemotactic properties of these proteins (106, 111, 112). Two small, non-coding RNAs 
encoded by tarA and tarB are also located within the VPI (113, 114).  TarA regulates ptsG, a 
major glucose transporter, while TarB regulates the secreted TcpF before penetration into the 
intestinal epithelial layer (113, 114).  When mutated, the aldehyde dehydrogenase aldA does 
not show a defect in colonization; however it is coordinately regulated along with the tcp 
operon (115). TagA is a metal-dependent mucinase that acts to modify mucin proteins by 
cleaving them and potentially leading to enhanced binding of V. cholerae to the cell surface 
(116). More work is needed to elucidate the complete role of these and other VPI genes in 
disease. 
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Motility and Chemotaxis 
 Motility and chemotaxis have been extensively studied in regard to their roles in 
pathogenesis.  However, their roles in disease are highly debated as different strains, biotypes, 
mutations and animal models can show different, and sometimes opposite results (117-124). As 
mentioned previously, V. cholerae is a highly motile bacterium that has a single, polar flagellum.  
The flagellum is driven by sodium motive force. When genes involved in flagellum sodium 
uptake are mutated, under non-virulence inducing conditions, there CT and TCP production 
increased. This suggests a mechanism in which sodium concentration affects virulence gene 
expression (lower sodium levels lead to increased virulence gene expression), which would be 
an indirect effect of the flagellar action (125).  At the strain level using the classical biotype with 
the infant mouse model, it has been shown that non-motile strains, in which the genes involved 
in flagellar production have been mutated, are able colonize to similar levels as wild-type, 
motile strains (120).  Similar experiments have been carried out with the El Tor biotype and 
have shown opposite results: non-motile mutants were unable to colonize the infant mouse 
(126-128).  Even with the conflicting data, the current hypothesis is that motility is necessary in 
order to penetrate the mucus layer of the small intestine, which, in turn, gives V. cholerae 
access to the epithelial cells (40). 
 Chemotaxis has also been shown to be important for colonization and disease.  In the 
most general terms, chemotaxis is the movement of an organism either towards or away from a 
chemical stimulus.  There are three chemotaxis operons in the V. cholerae genome, but only 
one that is essential for chemotaxis (129, 130).  Like motility, the importance of chemotaxis in 
V. cholerae is controversial.  In one study, various genes of the El Tor biotype involved in 
12 
 
 
 
chemotaxis were deleted and colonization of the infant mouse intestine was determined.  Non-
chemotactic mutants colonized the intestine 70-fold better than WT (127).  However, the 
bacteria were found throughout the intestine, as opposed to only the lower half of the small 
intestine corresponding the lower jejunum and ileum, suggesting V. cholerae uses chemotaxis 
as a means to find a preferred site for colonization (40).  
 
ToxR Regulon 
 Transcription of the complex network of virulence genes from both the CTXφ and VPI is 
tightly coordinated by a regulatory cascade termed the “ToxR Regulon” (108). Although the 
virulence regulon is still often referred to as the ToxR regulon  for historical reasons, ToxR is not 
the transcriptional regulator of CT and TCP expression, but was simply the first regulator 
identified (108, 131). Instead, the coordinated expression of virulence genes is directly 
regulated by the transcriptional activator ToxT, and multiple regulatory proteins and factors 
affect the cascade to ensure that ToxT is only expressed under optimal environmental 
conditions (104, 132-134). ToxR and another transcriptional regulator, TcpP, control 
transcription of toxT (135-137). toxR is found in all Vibrio species as part of the ancestral 
genome and is constitutively expressed, while tcpP is located on the VPI, and thus found only in 
pandemic strains and expressed only under virulence inducing conditions (138-140). 
 ToxR is an integral membrane regulatory protein homologous with the OmpR family of 
proteins that contain a cytoplasmic winged helix-turn-helix DNA-binding domain (141, 142). 
ToxS, another integral membrane protein, acts to increase dimerization of ToxR, which is 
needed for full ToxR activity in order to then initiate toxT transcription (143, 144). At the toxT 
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promoter, it is thought that ToxR acts as an enhancer of TcpP binding as evidence suggests that 
although TcpP can interact directly with the RNA polymerase, ToxR is necessary to activate toxT 
transcription (145). ToxR/S bind to the toxT promoter between -100 and -69 with respect to the 
transcriptional start site as shown by DNase I footprinting in this region (137). ToxR also 
regulates transcription of the outer membrane porins OmpU and OmpT.  ToxR upregulates 
expression of ompU, which encodes a porin that is protective against the negative effects of 
bile (146-148).  ompU transcription by ToxR is also increased in the presence of bile (149). In 
contrast, ToxR downregulates expression of ompT. OmpT is expressed in the environment and 
under nutrient limited conditions (150). 
TcpP interacts with another membrane protein, TcpH, to regulate transcription of toxT 
in combination with ToxR/S (135).  TcpP is also a member of the OmpR family of proteins, with 
a homologous cytoplasmic domain (142). TcpH is required for the stability of TcpP, as in the 
absence of it, TcpP is rapidly degraded by the metalloprotease YaeL (151, 152).  In conditions 
not permissive for virulence, degradation of TcpP occurs even when TcpH is present (151).  YaeL 
targets the periplasmic domain of TcpP and is also present in conditions not permissive for 
virulence (151). Taurocholate, a bile salt found in the intestine, has been shown to induce 
dimerization of TcpP leading to increased activation potential of toxT (153).  TcpP/H binds to 
the toxT promoter between -51 and -32 relative to the transcriptional start site, and TcpP alone 
can activate expression of toxT when over-expressed by relying on its DNA-binding specificity to 
locate the promoter (137, 154).  
As mentioned previously, tcpPH is not expressed constitutively. Instead, expression of 
these genes is dependent on the transcription regulators AphA and AphB (155, 156). AphA 
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binds to the tcpPH promoter between -101 and -71, while AphB binds between -78 and -43 
(157). AphA is a dimer that is a member of the winged helix transcription factor superfamily 
(158), while AphB is a LysR-type regulator protein (155). AphB interacts directly with AphA on 
the DNA to activate tcpPH and changes conformation in response to pH and oxygen level 
changes (159-161).  tcpPH is also negatively regulated by cAMP receptor protein (CRP) and 
PepA (131, 157, 162, 163). CRP, normally important in metabolism, can bind to the promoter 
and repress expression by competing at the same binding sites as AphA and AphB (157). The 
mechanism of PepA repression is still unclear; however it is known that PepA responds to 
changes in pH and temperature (162).  Under virulence non-permissive conditions, PepA 
represses transcription of tcpPH (162). 
 
Signaling Systems 
 Quorum sensing is a system used to allow communication between bacteria in order to 
change gene expression in response to cell density through the production of small molecules 
called autoinducers (164). These autoinducers are constitutively produced so that at low cell 
density quorum sensing is turned off due to low concentration of the autoinducers and at high 
cell density bacteria sense the presence of autoinducers and alter their gene expression 
patterns. V. cholerae uses the system to influence virulence gene expression by downregulating 
CT and TCP at high cell density (64, 157, 165, 166).  There are three quorum sensing systems in 
V. cholerae that control HapR, which in turn, represses transcription of aphA (165, 166).  Two 
systems are similar, each employing an autoinducer and a sensor kinase.  The first system uses 
the autoinducer CAI-1 and sensor kinase CqsS, and the second system uses the autoinducer AI-2 
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and the sensor kinase LuxQ, with its periplasmic partner LuxP (167).  Under low cell density the 
kinases phosphorylate LuxU, which in turn transfers the phosphate group to LuxO, and then this 
initiates transcription of four small RNAs called qrr1-4 (168, 169).  These sRNAs bind to the 
5’UTR of HapR mRNA along with Hfq in order to initiate its degradation (170, 171). Under this 
condition, there is no HapR and therefore aphA is expressed and virulence gene expression can 
occur. Conversely, at high cell density, the autoinducers bind to their respective sensor kinases, 
which then act as phosphatases to remove the phosphates from LuxU and LuxO. LuxO now can 
no longer activate transcription of qrr1-4 and HapR can then made. With HapR produced, aphA 
is now repressed and virulence gene expression is downregulated (165). The third quorum 
sensing system uses VarS/VarA proteins in order to activate LuxO (170).  VarS/VarA is a two-
component signaling system that activates CsrB, CsrC, and CsrD, while deactivating CsrA. When 
CsrA is inactivated, LuxO can become phosphorylated and act as it does in the other two 
systems (170). Even though the direct correlation between quorum sensing and virulence gene 
expression seems straightforward, there are some epidemic El Tor strains that have a mutated 
hapR that leaves it non-functional, suggesting that quorum sensing is not important for causing 
human disease (64). Therefore, more research is needed to fully determine the role that 
quorum sensing plays in virulence gene regulation. HapR also controls other genes involved in 
virulence expression in addition to aphA such as HapA and VPS operon (172). HapR increases 
expression HapA, a hemagglutin/protease involved in mucosal escape in El Tor strains, while in 
turn, represses the VPS operon, which is involved in biofilm formation. At low cell density, 
biofilms are activated as HapR is not present (173). 
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 In addition to quorum sensing, V. cholerae is also able to use the second messenger 
3’,5’-cyclic diguanylate (c-di-GMP) as part of a signaling system to change gene expression 
(174). With this system, c-di-GMP levels are modulated in response to some first messenger 
and these different c-di-GMP levels directly correspond to changes on the cell surface (175). C-
di-GMP production is controlled by diguanylate cyclase, and increased levels of c-di-GMP lead 
to increased expression of the biofilm VPS genes, extracellular protein secretion system and 
mannose sensitive hemagglutinin type IV pilus biogenesis genes (176, 177). Increased levels of 
c-di-GMP also correlate to decreased expression of the fla genes involved in the production of 
flagella (176, 177). The levels of c-di-GMP are controlled directly by the VieSAB system (178). 
VieA is a phosphodiesterase that acts to decrease the levels of intracellular c-di-GMP.  
Decreased c-di-GMP expression correlates with maximal CT production (174).  
 
The Virulence Gene Transcription Activator ToxT 
 ToxT is a 32 kDa, 276 amino acid protein that acts as the main virulence gene regulator 
for ctxAB and tcp (104, 132-134). It is a member of the AraC/XylS family of proteins, sharing 
homology in the C-terminal domain (CTD) (179-181). The CTD is about 100 amino acids and 
contains two helix-turn-helix DNA-binding motifs (179, 181). The N-terminal domain (NTD) 
spans amino acids 1-160 and the CTD consists of amino acids 170-276 with a small linker region 
of ten amino acids between the two domains (182). The NTD does not share sequence 
similarity to other AraC/XylS family members, but the ToxT crystal structure does show some 
secondary structural homology to AraC despite having very little amino acid identity (182). 
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 ToxT not only activates transcription of the genes encoding CT and TCP, but also 
activates transcription of other virulence genes including acfA, acfD, aldA, tagA, tcpI, and the 
RNAs tarA and tarB (109, 110, 113, 114, 183). To activate these genes, ToxT binds to 13 base 
pair degenerate sequences termed toxboxes, each containing a poly-T tract at the 5’ end of the 
binding site. Toxboxes are located upstream of the -35 promoter element that is recognized as 
part of the RNA polymerase binding site (183).  This toxbox location suggests that ToxT must 
directly interact with the RNA polymerase α subunits to stimulate transcription (184). 
Depending on the particular virulence gene in question, the toxboxes can have different 
arrangements. At the promoters of tcpA, ctxAB, and tarA there are two toxboxes arranged as 
direct repeats (114, 183).  For acfA, acfD, tagA, and tcpI there are two toxboxes arranged as 
inverted repeats, with the divergently transcribed acfA and acfD sharing the same toxboxes 
(110, 183, 185). In contrast, aldA only contains one toxbox (109). ToxT can also activate its own 
transcription through its role in activating transcription of the tcp operon, within which the toxT 
gene is located (133, 134). The ability of ToxT to regulate its own expression is thought to allow 
for finer control of virulence gene expression. 
 Members of the AraC/XylS family include some proteins that act as dimers, including 
AraC, RhaS, and RegA and some member that act only as monomers, including MarA, SoxS, and 
Rob (185-188).  The ability of ToxT to act as either a monomer or a dimer at the promoters it 
activates has been quite controversial. As most ToxT-activated promoters contain two 
toxboxes, it is hypothesized that ToxT acts as a homodimer, but, aldA only has one toxbox 
suggesting that ToxT does not require dimerization in order to activate the virulence gene 
promoters (109). The NTD of ToxT has been shown to be involved in dimerization through 
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studies using the LexA dimerization assay as well as bacterial two-hybrid systems (182, 189-
192). Interestingly, full length, intact ToxT has never been observed to dimerize and the ToxT 
crystal structure is of a monomeric protein. Virstatin, a small molecule inhibitor of virulence 
gene expression, has been proposed to act by decreasing ToxT dimerization (192, 193).  Other 
studies, however, have shown that ToxT can bind to promoters as a monomer, such as at the 
tcpA promoter (110, 183). In this experiment, the spacing between the toxboxes was increased 
and using DNA-footprinting it was shown that ToxT was still able to protect the DNA (110, 183). 
However, when the spacing was greatly altered, ToxT was not able to activate transcription 
indicating that the distance between the sites is important for full activation. Even though there 
has been extensive work on the dimerization ability of ToxT, more work still needs to be done 
to understand its role in ToxT function. 
 
Effectors of ToxT 
 There are both positive and negative effectors that affect the ability of ToxT to activate 
transcription.  The histone-like protein H-NS is a global repressor protein of transcription and is 
found in many gram-negative bacteria, including V. cholerae (194). H-NS is able to oligomerize 
and occupy multiple binding sites near promoters such as ctxAB, toxT and tcpA, where it acts to 
repress transcription (195, 196). H-NS has also been shown to compete with ToxT at the ctxAB 
promoter, suggesting a mechanism by which H-NS must be displaced by ToxT in order to de-
repress transcription of the virulence gene it is acting upon (197).  
 To induce virulence in vitro, different growth conditions are used for the two different V. 
cholerae biotypes.  For the classical biotype, 30°C, Luria-broth (LB) at pH 6.5, and aeration are 
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sufficient for maximal activation of ctxAB and tcp (198). In contrast, for the El Tor biotype, a 
biphasic culture condition termed AKI conditions is used for maximal production of CT and TCP.  
Under AKI conditions, the culture is grown statically at 37°C in AKI peptone medium for several 
hours and then switched to aeration conditions for an additional two hours (199-201). Although 
the two conditions differ, they each allow for maximal ToxT production and therefore maximal 
CT and TCP production. Another growth condition that was found to result in CT production in 
both biotypes was in rich medium containing fresh sodium bicarbonate  statically at 37°C (202). 
This will be described more below. 
 While the laboratory growth conditions described above are artificial and do not 
resemble conditions that would be present in the human small intestine, effectors of ToxT 
activity can be found in the environment that V. cholerae inhabits.  Using in vitro conditions has 
allowed the elucidation of some of the chemical signals necessary for virulence induction, but 
as the small intestine is at 37°C and under static conditions, it is obvious that there must be 
certain in vivo signals that allow for virulence production to occur. These include temperature, 
pH, and various host chemicals such as bicarbonate and bile (160, 202-205). The chemical 
bicarbonate has been shown to be a positive effector of ToxT activation of CT and TCP (202). 
Bicarbonate is found in the same place where V. cholerae colonizes to act as a protective buffer 
in the small intestine and is secreted by the intestinal epithelial cells (206).  Although it does not 
increase the production of ToxT, bicarbonate has been shown to increase the ability of ToxT to 
activate virulence gene transcription by enhancing DNA binding (202, 207). 
 Bile, conversely, is a negative regulator of ToxT activity (203-205). Secreted by the gall 
bladder, bile contains many different components, including bile salts, saturated and 
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unsaturated fatty acids, cholesterol, proteins, and phospholipids that normally act together to 
emulsify fats in the lumen of the small intestine and act as a bactericide. When added in vitro to 
V. cholerae, bile is shown to cause decreased production of TCP and CT, and increased motility, 
biofilm formation, and outer membrane protein quantities (203-205).  In one study, bile was 
fractionated to determine the components responsible for decreased virulence activation by 
ToxT (204). From this information, it was shown that only the unsaturated fatty acid (UFA) 
components are responsible for decreased virulence (204). Of the UFA components, oleic, 
linoleic, and arachidonic acids are the most abundant UFA components of bile (204).  Linoleic 
acid, the UFA primarily used in the studies described in this dissertation, is an 18-carbon fatty 
acid that contains two cis-double bonds. Upon resolution of the crystal structure of ToxT, cis-
palmitoleic acid, another UFA, was found buried in the NTD (182). In one study, cis-palmitoleic 
acid was only ~0.5% of the total fatty acid content in bile, as compared to oleic acid, which 
accounted for ~23.5%, linoleic acid accounted for ~14%, and arachidonic acid accounted for 
approximately ~3% of the total UFA content in bile (204). However, this fractionation was done 
with ox bile. A similar study in 1987 fractionated the fatty acid components in 24 healthy, adult 
human volunteers and found slightly different amounts: ~2.68% for palmitoleic acid, ~12.09% 
for oleic acid, ~32.83% for linoleic acid and ~5.64% for arachidonic acid with the rest composed 
of saturated fatty acids (208). In this study, linoleic acid composed the largest proportion of 
UFA, as opposed to the previous study in which oleic acid accounted for the largest proportion. 
 The aim of this work is to better understand how V. cholerae responds to a change from 
environmental to host conditions.  This includes work aimed at identifying the mechanism by 
which linoleic acid decreases virulence gene expression by acting through ToxT. Conjugated 
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linoleic acid is currently on the market as a weight loss supplement proposed to inhibit fat 
absorption and this is also studied as it could potentially be used as either a prophylactic or as a 
therapy to reduce CT production and thus disease duration and intensity. In current era in 
which antibiotic resistance is becoming a severe problem, therapeutics that inhibit 
pathogenesis but do not affect bacterial survival are likely to become much more attractive as 
the bacteria are unlikely to develop resistance against them.  
A list of all strains used is included in Table 1. Together, this dissertation enhances both 
our basic understanding of virulence gene regulation and host signals during cholera and 
translates this newly acquired knowledge into a potential cholera therapeutic that is safe for 
human consumption and is inexpensive. 
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Strain Plasmid Description Parent 
Strain 
Source Chapter 
JW 467 pMAL-c2e-ToxT Escherichia coli BL21(DE3)  New 
England 
Biolabs 
1-4 
JW 1560 pJW 407 MBP-ToxT for protein 
purification 
JW 467 Lab 
Collection 
1-4 
JW 9  Vibrio cholerae classical 
strain O395 
 Lab 
Collection 
1-4 
JW 150  ∆toxt JW 9 Lab 
Collection 
1 
VJ740  ∆toxt-helix-turn-helix O395 (132) 1 
JW 18 pJW 54 PtcpA::lacZ in pTL61t JW 9 Lab 
Collection 
1 
JW 441 pJW 211 PctxAB::lacZ in pTL61t JW 9 Lab 
Collection 
1 
JW 87 pJW 82 PaldA::lacZ in pTL61t JW 9 Lab 
Collection 
1 
JW 97 pJW 89 PtagA::lacZ in pTL61t JW 9 Lab 
Collection 
1 
JW 86 pJW 81 PacfA::lacZ in pTL61t JW 9 Lab 
Collection 
1 
JW 89 pJW 84 PacFD::lacZ in pTL61t JW 9 Lab 
Collection 
1 
JW 169 pJW 91 PtcpI::lacZ in pTL61t JW 9 Lab 
Collection 
1 
JW 666 pJW 308 PtoxT::lacZ in pTL61t VJ740 Lab 
Collection 
1 
JW 329 pJW 179 PtcpP::lacZ in pTL61t JW 9 Lab 
Collection 
1 
JW 515 pJW 54 PtcpA::lacZ in pTL61t JW 150 Lab 
Collection 
1 
JW 1809 pJW 211 PctxAB::lacZ in pTL61t JW 150 Lab 
Collection 
1 
JW 167 pJW 82 PaldA::lacZ in pTL61t JW 150 Lab 
Collection 
1 
JW 168 pJW 89 PtagA::lacZ in pTL61t JW 150 Lab 
Collection 
1 
JW 165 pJW 81 PacfA::lacZ in pTL61t JW 150 Lab 
Collection 
1 
JW 166 pJW 84 PacFD::lacZ in pTL61t JW 150 Lab 
Collection 
1 
JW 169 pJW 91 PtcpI::lacZ in pTL61t JW 150 Lab 
Collection 
1 
CRP4 pCRPhis CRPhis in pBAD33 K2294 Lab 
Collection 
1 
JW 714  O395tcpA::lacZ ∆toxt JW 150 Lab 
Collection 
2 
JW 1066 pJW 407 MBP-ToxT JW 714 Lab 
Collection 
2 
JW 1414 pJW 501 MBP-ToxT (G100A) JW 714 Lab 
Collection 
2 
Table 1. List of strains used in this work.  
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Strain Plasmid Description Parent 
Strain 
Source Chapter 
JW 1415 pJW 502 MBP-ToxT (D101A) JW 714 Lab 
Collection 
2 
JW 1416 pJW 503 MBP-ToxT (L102A) JW 714 Lab 
Collection 
2 
JW 1417 pJW 504 MBP-ToxT (M103A) JW 714 Lab 
Collection 
2 
JW 1418 pJW 505 MBP-ToxT (I104A) JW 714 Lab 
Collection 
2 
JW 1419 pJW 506 MBP-ToxT (R105A) JW 714 Lab 
Collection 
2 
JW 1420 pJW 507 MBP-ToxT (N106A) JW 714 Lab 
Collection 
2 
JW 1421 pJW 508 MBP-ToxT (L107A) JW 714 Lab 
Collection 
2 
JW 1422 pJW 509 MBP-ToxT (Y108A) JW 714 Lab 
Collection 
2 
JW 1423 pJW 510 MBP-ToxT (S109A) JW 714 Lab 
Collection 
2 
JW 1424 pJW 511 MBP-ToxT (E110A) JW 714 Lab 
Collection 
2 
JW 1469 pJW 520 MBP-ToxT (L107F) JW 714 Lab 
Collection 
2 
JW 1470 pJW 521 MBP-ToxT (R105K) JW 714 Lab 
Collection 
2 
JW 1471 pJW 522 MBP-ToxT (R105Q) JW 714 Lab 
Collection 
2 
JW 1472 pJW 523 MBP-ToxT (L107S) JW 714 Lab 
Collection 
2 
JW 1474 pJW 525 MBP-ToxT (N106S) JW 714 Lab 
Collection 
2 
JW 1475 pJW 526 MBP-ToxT (N106F) JW 714 Lab 
Collection 
2 
JW 1556 pJW 536 MBP-ToxT (L114A) JW 714 Lab 
Collection 
2 
JW 1582 pJW 538 MBP-ToxT (R105A, N106A) JW 714 Lab 
Collection 
2 
JW 690  O395tcpA::lacZ JW 9 Lab 
Collection 
3 
JW 75  E. coli SM10 λpir  Lab 
Collection 
4 
JW 751 pJW316 PtcpA::gfp JW 690 Lab 
Collection 
4 
JW 422 pFD1 mariner transposon JW 75 Lab 
Collection 
4 
JW 947  ∆pckA JW 690 Lab 
Collection 
4 
JW 939  ∆pepcase JW 690 Lab 
Collection 
4 
JW 940  ∆icd JW 690 Lab 
Collection 
4 
JW 1125 pckA pckA in pBAD33 in ∆pckA JW 947  Lab 
Collection 
4 
Table 1 cont. List of strains used in this work. 
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CHAPTER ONE 
The mechanism for inhibition of ToxT activity by the unsaturated fatty acid components of bile 
in Vibrio cholerae 
ABSTRACT 
The gram-negative curved bacillus Vibrio cholerae causes the severe diarrheal illness 
cholera.  During host infection, a complex regulatory cascade results in production of ToxT, a 
DNA-binding protein that activates the transcription of major virulence genes that encode 
cholera toxin (CT) and toxin-coregulated pilus (TCP). Previous studies have shown that bile and 
its unsaturated fatty acid (UFA) components reduce virulence gene expression. Bile is likely an 
important chemical recognized by V. cholerae upon entering the host. However, the 
mechanism for the bile-mediated reduction of TCP and CT expression has not been defined. 
There are two likely hypotheses for this effect: 1) UFAs decrease DNA binding by ToxT or 2) 
UFAs decrease dimerization of ToxT. To determine whether bile/UFAs affect DNA binding by 
ToxT, we first determined that UFAs, specifically linoleic acid, can enter V. cholerae when added 
exogenously. We then performed electrophoretic mobility shift assays with ToxT on various 
virulence promoters in the presence or absence of UFAs. The results indicate that UFAs can 
enter the bacteria, where they can then interact with ToxT in the cytoplasm to decrease ToxT 
binding to DNA even at a promoter having only one ToxT binding site. This suggests a 
mechanism in which UFAs do not affect dimerization but can affect monomeric ToxT binding to 
DNA.   
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INTRODUCTION 
V. cholerae, a gram-negative curved bacillus possessing a single polar flagellum, is the 
causative agent of cholera. Cholera is a diarrheal disease contracted by consuming 
contaminated food or water and is characterized by severe diarrhea that leads to dehydration, 
and can ultimately cause death if left untreated. Each year, there are an estimated 1.4-4.3 
million cholera cases and 20,000-142,000 deaths from the disease (14, 15). In order to cause 
disease, V. cholerae must colonize the duodenum, where it is able to express its virulence genes, 
including the most important of these: toxin co-regulated pilus (TCP) and cholerae toxin (CT). 
TCP is required for intestinal colonization, while CT is responsible for the massive secretion of 
electrolytes and water into the lumen, causing diarrhea. These virulence genes and others are 
regulated by the major virulence transcription activator ToxT.   
Virulence gene expression is regulated by what is historically known as the ToxR regulon 
(108, 131).  toxT transcription is activated by two sets of inner membrane proteins, ToxR/ToxS 
and TcpP/TcpH, that bind upstream of toxT, as well as by a ToxT positive feedback loop (133-
137). ToxT is a 32-kDA member of the AraC/XylS transcriptional regulator family, having a 
conserved 100-amino-acid DNA binding domain, consisting of two helix-turn-helix motifs, in its 
C-terminal domain (CTD).  Located upstream of all ToxT-activated genes are 13-bp degenerate 
DNA sequences called toxboxes that vary in configuration at individual genes (110, 114, 183-
185). ToxT directly controls transcription of genes encoding not only TCP and CT, but also other 
accessory virulence genes including acfA, acfD, aldA, tagA, tarA, tarB, and tcpI (109, 110, 113, 
114, 183). Except for the aldA promoter, in which there is a single toxbox, there are two 
toxboxes present at ToxT-activated promoters (109, 110, 114, 183, 185). ToxT can bind to single 
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toxboxes as a monomer but it is thought that full activation only occurs upon ToxT dimerization 
on the DNA, at least at some genes (110, 183).  The ToxT N-terminal domain (NTD), does not 
share significant sequence homology with other proteins, but has some structural similarity to 
the AraC NTD, which is the domain necessary for AraC dimerization and arabinose binding 
(182).  NTDs of ToxT have been shown to interact when separated from the CTD, although the 
true role of dimerization in ToxT function is not fully understood (109, 182, 189-193).   
A number of host and environmental factors affect ToxT activity, including temperature, 
pH, bile and bicarbonate (160, 202-205). Bile is produced by the liver and then subsequently 
stored in the gallbladder.  Upon eating, bile is released into the duodenum where it acts to 
solubilize lipids. Bile itself is a complex, heterogeneous mixture that includes bile salts, 
cholesterol, bilirubin, and saturated and unsaturated fatty acids (UFAs).  V. cholerae encounters 
bile early during infection and it is proposed to be a natural effector of ToxT as it is found in the 
same places that V. cholerae colonizes (203-205). V. cholerae has reduced virulence gene 
expression in the presence of bile and/or UFAs, with increased motility gene expression, biofilm 
formation, the induction of efflux pumps, and increased amounts of outer membrane proteins 
OmpU, OmpT and TolC (146, 203, 204, 209-211). Bile and its UFA components have been 
previously shown to decrease CT and TCP production, but the mechanism of this effect on 
virulence gene expression levels is not understood (203, 204). Bile also has another role, in that 
it is able to act as a bactericide for the benefit of the host, but enteric bacteria, such as V. 
cholerae, are not only adapted to live in the presence of bile, but potentially can recognize bile 
as a signal to ensure survival in the host (203, 205). Another negative regulator of ToxT is 
virstatin, which is a small, synthetic molecule that has been previously shown to decrease ToxT 
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activity (192, 193). The mechanism for this has been proposed to be by inhibiting ToxT 
dimerization (192).  Whether UFAs and virstatin inhibit ToxT activity via the same mechanism is 
unknown. 
In this study we show that UFAs, specifically the unsaturated fatty acid linoleic acid, are 
able to enter the bacterial cell where ToxT is also present in the cytoplasm.  We report that 
linoleic acid and virstatin cause decreased transcription of ToxT-controlled virulence genes and 
determined that the mechanism by which this happens is decreased binding affinity at ToxT-
activated promoters, regardless of the number or configuration of the toxboxes.  Our results 
indicate that UFAs decrease ToxT binding to DNA even at promoters having one ToxT binding 
site, suggesting a mechanism in which UFAs do not only affect the ability of ToxT to dimerize, 
but also affect the ability of monomeric ToxT to bind to DNA. These results give us a clearer 
understanding of the regulatory networks controlling virulence gene expression during human 
infection.  
MATERIALS AND METHODS 
V. cholerae strains and growth conditions. All V. cholerae strains used in the study are 
derived from classical biotype O395.  Strains were maintained in Luria Broth (LB) containing 
20% glycerol and stored at -70°C. All promoter::lacZ fusions used for β-galactosidase assays 
were made in plasmid pTL61T as described in previous studies (202, 207). Overnight cultures 
were grown for ~16 hours at 37°C in LB and then diluted 1:40 into LB pH 6.5 at 30°C for 
virulence inducing conditions in the presence or absence of freshly prepared .05% bile (sodium 
choleate), 160µM linoleic acid, or 100µM virstatin. V. cholerae strains were grown with 
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antibiotic concentration of 100µg/mL streptomycin and strains with the plasmid pTL61T were 
grown with 100µg/mL ampicillin. 
Western blot analysis of ToxT. Immunodetection of ToxT was performed using the 
same procedure as previously described (202). Briefly, bacteria were harvested after inducing 
conditions either DMSO only, 160µM linoleic acid, or with 100µM virstatin.  Cells were 
normalized at an optical density of 600nM and resuspended in 2x protein buffer. Samples were 
then boiled, separated by 14% SDS-PAGE, blotted, and blocked for 30 minutes in TBS buffer. 
After blocking, the blots were incubated overnight in a 1:2,500 dilution of rabbit polyclonal anti-
ToxT serum, washed three times in TBS buffer, and secondary goat anti-rabbit IgG conjugated 
to alkaline phosphatase (AP) was used at a dilution of 1:5000 (Southern Biotech). Blots were 
washed again and then developed using immune-BCIP (MP Biomedicals).  
14C linoleic acid uptake and fractionation. V. cholerae classical biotype strain O395 was 
grown overnight in LB at 37°C, subcultured 1:40 in LB pH 6.5, and grown for two hours in the 
absence of linoleic acid. At two hours, 0.1μCi 14C-radiolabeled linoleic acid (58.2mCi/mmol) 
(Perkin-Elmer) was added for each milliliter of the subculture. Upon addition of the 
radiolabeled linoleic acid, 1 mL of the culture was immediately centrifuged, and the 
supernatant saved to compare to cell pellet cpms. The cell pellet was washed 3 times with 1 mL 
of PBS and centrifuged each time. Cell pellets were resuspended in 100μL PBS and added to 
5mL Scintillation cocktail (Fisher Scientific). The same procedure was followed for other aliquots 
of the subculture at times 5, 15 and 30 minutes. After uptake, cpm was measured for each time 
point using an LS6000IC liquid scintillation counting system (Beckman). 
29 
 
 
 
 14C linoleic acid fractionation assay. After overnight growth, V. cholerae O395 classical 
biotype was subcultured 1:40 in the absence of linoleic acid.  After 2 hours, 0.1μCi 14C-
radiolabeled linoleic acid (58.2mCi/mmol) (Perkin-Elmer) was added to one milliliter of the 
subculture and incubated at room temperature. After one hour, the bacteria were harvested by 
centrifugation and washed three times in PBS. Bacteria were then resuspended in 20mM Tris-
HCl, pH 8.5 and 500 mM NaCl) and freeze-thawed in an ethanol and dry ice bath, then thawed 
at 37°C. This process was repeated for a total of three freeze-thaw cycles. The bacteria were 
then fractionated by centrifugation for 10 min at 15,000 x g to separate the 
periplasm/membrane and cytoplasm.  A Western Blot was performed to ensure efficient 
fractionation (data not shown). The cytoplasm was taken as the supernatant and the pellet was 
resuspended in PBS. Each fraction was then measured for cpm of each fraction using a LS6000IC 
liquid scintillation counting system (Beckman). 
β-galactosidase assays. Strains to be analyzed were grown overnight in LB at 37°C and 
then subsequently subcultured 1:40 into LB pH 6.5 in the presence or absence of 160µM 
linoleic acid dissolved in DMSO.  Cultures were grown under virulence inducing conditions 
(aeration at 30°C) for 3 hours and then analyzed.  The β-galactosidase assay was then 
performed following the same established protocol (212). 
qRT-PCR. As in previous assays, after overnight growth, V. cholerae classical biotype 
O395 was subcultured 1:40, either with or without 160µM linoleic acid. RNA from three 
biological samples in each condition was extracted using the RNeasy Bacteria Protect Mini Kit 
(Qiagen) and manufacturer’s protocols were followed. DNA contamination was removed using 
an on-column RNase-free DNase kit (Qiagen) and confirmed free of DNA by the absence of 
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bands using logarithmic PCR. To measure the relative mRNA levels of tcpA and aldA the 
following primers were used: forward tcpA (5’-ACGCAAATGCTGCTACACAG-3’) reverse tcpA (5’-
CCCCTACGCTTGTAACCAAA-3’), and forward aldA (5’-TTGGTGGGCATCCTAACAAT-3’) reverse 
aldA (5’-ACACCGGCACCTAAACCATA-3’).  qRT-PCR was performed using one-step SYBR green 
Mastermix (Invitrogen) and the following program: cDNA synthesis for 10min. at 55° C, 
denaturing step for 5min. at 95° C, followed by 35 cycles of 95° C for 10 s, then 55° C for 30 s. 
The level of each mRNA was normalized to the level of rpoB using primers forward rpoB (5’-
ACCTGAAGGTCCAAACATCG-3’) and reverse rpoB (5’-CAAAACCGCCTTCTTCTGTC-3’). Relative 
levels of transcript with the addition of linoleic were calculated using 2-ΔΔCT and analyzed 
comparing the ΔΔCT values as previously described (213). 
Protein Purification. Maltose binding protein-ToxT fusion (MBP-ToxT) and MBP-CRP 
purification was performed as previously described using E. coli strain BL21(DE3) with the 
plasmid pMAL-c2E carrying either MBP-ToxT or MBP-CRP (207, 214). Briefly, after MBP-ToxT or 
MBP-CRP induction by IPTG, cells were lysed by French press, run over an amylose column, and 
fractions containing MBP-ToxT or MBP-CRP were saved and dialyzed into 50mM Na2HPO4 (pH 
8.0), and 100mM NaCl and then dialyzed into the same solution containing 20% glycerol to save 
as freezer stock at -80° C. 
 Electrophoretic mobility shift assays (EMSA) and binding curve analysis. EMSAs were 
performed as previously described (214). Purified MBP-ToxT, or MBP-CRP with cAMP (New 
England Biolabs), was incubated with DNA probes made by PCR from the promoter sequence of 
interest using one primer radiolabeled with γ-32P (Perkin-Elmer) by T4 polynucleotide kinase 
(New England Biolabs). Binding reactions contained various amounts of MBP-ToxT with 
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constant 10 µg/mL salmon sperm DNA as nonspecific competitor, 10mM Tris-acetate (pH 7.4), 
1mM Potassium EDTA (pH 7.0), 100mM KCl, 1mM dithiothreitol (DTT), 0.3mg/mL bovine serum 
albumin (BSA) and 10% glycerol in a volume of 30µL. To each reaction, a constant concentration 
of the labeled DNA probe was added. In reactions containing linoleic acid, the final 
concentration was 32µM for each reaction, and for reactions containing virstatin, the final 
concentration was 50µM, except at the aldA promoter where a higher concentration of 100µM 
was used. All other reactions contained 3.33% (1μL in 30μL) DMSO as a solvent control. Binding 
reactions were incubated for 30 minutes at 37°C and then loaded into a 6% polyacrylamide gel 
at 4°C. Gels were dried for 1 hour and then analyzed by autoradiography. 
 Binding curve analysis.  Autoradiographs were analyzed using ImageJ software (NIH) as 
previously described with nonspecific binding omitted from further analysis (207). Briefly, to 
determine the Kd for samples containing either linoleic acid or virstatin and compared to 
protein bound to DNA without inhibitor, the percent of protein bound with labeled DNA was 
determined for each lane. This was then fit to the equation 
%Bound=Bmax*[Protein]
h/(Kd
h + [Protein]h) with Bmax constraint set to 100 using Graphpad Prism 
5 software. The Kd values for each condition were compared to each other using the extra sum 
of squares F test to determine if the two values were statistically different.  
RESULTS 
ToxT protein is produced in the presence of linoleic acid. Previous work has 
demonstrated that UFAs inhibit virulence gene expression by acting through ToxT (204). Oleic 
acid has been previously shown to negatively regulate TCP and CT expression levels (182). In 
preliminary experiments, we determined that linoleic acid had the strongest negative effect on 
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ToxT activity of several different UFAs tested (data not shown), and previous studies have 
shown that linoleic acid makes up the largest proportion of unsaturated fatty acid content in 
human bile (208). To date, direct interaction of linoleic acid and ToxT has not been observed, 
although a palmitoleic acid molecule was visualized within the ToxT NTD in the solved crystal 
structure (182).  To begin our study, we investigated whether ToxT protein production was 
affected by the addition of linoleic acid in the media. It had been previously determined that 
there are comparable levels of toxT expression in cultures grown with and without linoleic acid 
(204). To confirm this, we analyzed the β-galactosidase production from a toxT::lacZ reporter 
plasmid in V. cholerae grown in the presence or absence of linoleic acid (Figure 1A). When V. 
cholerae was grown under virulence-inducing conditions (LB pH=6.5, aeration) in the presence 
of linoleic acid, the amount of β-galactosidase activity indicated that there was no statistically 
significant difference (P=.799) in toxT expression whether the culture had linoleic acid or lacked 
it. This is consistent with previous data confirming that linoleic acid does not 
affect toxT transcription.  
To further examine the effect of linoleic acid on ToxT, and confirm that there were no 
effects of linoleic acid on translation, we carried out Western blot analysis to assess the ToxT 
protein levels (Figure 1B).  V. cholerae was grown under virulence-inducing conditions in the 
presence or absence of linoleic acid and cell extracts were harvested. ToxT-specific polyclonal 
antibodies were used to detect protein levels. No differences in ToxT levels were observed 
regardless of the presence or absence of linoleic acid, as a ToxT-specific band was visible in 
Western blots at the same intensity under both conditions (Figure 1B, lanes 4 and 5).  This band 
was not detected in the ΔtoxT control strain (Figure 1B, lane 3).  Thus, ToxT was stably 
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produced regardless of the presence of linoleic acid while bacteria were grown under virulence-
inducing conditions. 
Linoleic acid enters the V. cholerae cytoplasm. As ToxT protein levels were roughly 
equivalent with or without linoleic acid, we next assessed whether a direct interaction between 
linoleic acid and ToxT would be possible.  Such an interaction would require that linoleic acid be 
imported into the bacterial cytosol. To determine whether this occurs, we performed an uptake 
assay using radiolabeled linoleic acid (Figure 2).  V. cholerae was subcultured under virulence-
inducing conditions for two hours and then 14C-labeled linoleic acid was added to the culture.  
Aliquots of the culture were taken at times 0, 5, 15, and 30 minutes after addition of 
radiolabeled linoleic acid and radioactivity was quantified by a scintillation counter. The amount 
of radioactivity found in the cell pellet was compared to the supernatant.  Results from this 
assay show that linoleic acid enters the bacteria at a linear rate with a best-fit line equation of y 
= 3421.3x + 30974 and an R2-value of .969.   
These data, however, do not indicate whether linoleic acid is present inside the 
bacterium or simply associated with the cell surface or outer membrane. To determine whether 
linoleic acid enters the cytosol, 14C-labeled linoleic acid was added to V. cholerae cultures 
grown under virulence-inducing conditions and then the bacteria were fractionated into 
membrane and cytoplasmic portions. This allowed us to see where in the bacterium linoleic 
acid was localized: the membrane, the cytoplasm, or both. Cultures were incubated for one 
hour with the radiolabeled linoleic acid.  These cultures were then pelleted and washed and the 
bacteria were separated into a cytoplasm and envelope fraction by multiple freeze-thaw cycles.  
The 14C-linoleic acid in each fraction was then quantified using a scintillation counter.  Results of 
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this experiment show that most of the linoleic acid is able to enter the cell (Figure 3). Directly 
comparing the amounts of linoleic acid in the two fractions showed that about 65% of the total 
14C-linoleic acid was present in the cytoplasmic fraction, while 35% was present in the 
membrane fraction. These data suggest that a significant fraction of extracellular linoleic acid 
can enter the cytosol, where it could then interact with ToxT.   
 Linoleic acid decreases ToxT activation of virulence gene transcription. tcpA and ctxAB 
expression have been previously shown to be inhibited by the addition of oleic acid to the 
media, but the effects of linoleic acid were not assessed in those studies (182). We assessed 
whether the inhibitory effect of linoleic acid that we observed extended to a variety of ToxT-
activated promoters with various ToxT binding site (toxbox) configurations, including tcpA, 
ctxAB, acfA, aldA, acfD, tagA, and tcpI. All of these promoters contain two toxboxes in either 
direct (tcpA, ctxAB) (183) or inverted repeat configurations (acfA, acfD, tagA, tcpI) (110, 183, 
185) except for aldA, which contains only one toxbox (109).  Plasmid-borne promoter-lacZ 
fusions were added to the wild-type V. cholerae classical strain as well as an otherwise isogenic 
ΔtoxT strain to measure transcriptional activity at these promoters with and without 160µM 
linoleic acid (Figure 4). At each of these promoters, linoleic acid had a statistically significant 
negative effect that prevented ToxT from fully activating transcription at the promoters in wild-
type O395. No effect of linoleic was observed in the ΔtoxT strain, confirming that linoleic acid 
acts through ToxT (Figure 4).   
 As the aldA promoter activity even in the absence of linoleic acid was much lower than 
at the other promoters, we performed quantitative real-time PCR (qRT-PCR) to compare 
expression levels of this promoter to expression levels of the tcpA promoter upon the addition 
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of linoleic acid. Bacteria were cultured using the same methods as the β-galactosidase assay 
and then the RNA was extracted. qPCR was then performed using primers for tcpA, and aldA, 
while using rpoB as the housekeeping gene control. The qPCR results showed that both tcpA 
and aldA were downregulated upon the addition of linoleic acid to the media (Figure 5). tcpA 
mRNA levels were lower when grown with linoleic acid, showing a mean fold decrease of 58.7 
and aldA levels decrease by a fold change of 28.4.  
There is decreased ToxT-DNA binding affinity with the addition of linoleic acid. To 
determine if linoleic acid is able to directly affect ToxT binding to DNA at the ToxT-activated 
promoters, we used EMSA. This method allows the binding pattern of ToxT to be characterized 
and give an estimation of the equilibrium dissociation constant, Kd, which represents the 
concentration of ToxT required for binding 50% of the DNA at equilibrium. The Kd values with 
and without linoleic acid will give a direct comparison of the effect of the fatty acid on the given 
promoter, as a higher Kd value indicates a lower binding affinity of ToxT for the DNA and a 
lower Kd value indicates higher binding affinity. 
To begin, we used the primary promoter in the tcp operon, PtcpA, as our 
32P-labeled DNA 
probe. Using purified MBP-ToxT, we added increasing amounts of protein to binding reactions 
with either DMSO alone (Figure 6A, lanes 1-7) or 32μM linoleic acid dissolved in DMSO 
(Figure6A, lanes 8-14) and a constant concentration of labeled DNA probe. Binding reactions 
were brought to equilibrium, and then run on a 6% polyacrylamide gel, followed by 
autoradiography. Densitometry analysis was performed using ImageJ software to calculate the 
percentage of bound DNA at each concentration of MBP-ToxT. A binding curve was made for 
each set of reactions to determine the percentage of bound DNA at each concentration of MBP-
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ToxT using Graphpad software (Figure 6B). In the case of MBP-ToxT binding to PtcpA DNA, the Kd 
without linoleic acid was 10.0nM and the Kd with linoleic acid was 33.1nM. These values are 
significantly different, and as the Kd with linoleic acid is greater than without, this indicates a 
lower ToxT binding affinity for PtcpA in the presence of linoleic acid. These data suggest there is 
likely a direct interaction between linoleic acid and ToxT as exhibited by the decreased binding 
affinity. 
To confirm that linoleic acid does not generally inhibit protein-DNA interactions, we 
used cyclic AMP receptor protein (CRP) as a control, together with the region upstream of tcpP 
as described above. We performed an EMSA comparing CRP binding with and without the 
addition of linoleic acid (Figure 6C) and performed densitometric analysis to determine the 
binding curves and Kd values. The binding curve and Kd values were statistically the same for 
CRP binding to PtcpP with or without linoleic acid (Figure 6D).  
We then wanted to determine the binding curves and Kd values at other ToxT-activated 
promoters, as there can be different toxbox orientations (Figure 7). As the equilibrium binding 
experiments on PtcpA showed a decrease in DNA binding upon addition of linoleic acid, we 
wanted to determine whether this occurred at promoters having alternative toxbox 
configurations, particularly at PaldA, which has only one toxbox (Figure 7.) If linoleic acid can 
decrease the binding affinity of ToxT for PaldA, it could indicate a mechanism other than UFAs 
interrupting ToxT dimerization (189).  The PctxAB contains two directly repeated toxboxes like 
PtcpA, albeit in the opposite direction and having different spacing distance (214). The rest of the 
ToxT-activated promoters previously mentioned, PacfA, PacfD, PtagA, and PtcpI each contain 
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toxboxes oriented in inverted repeat configuration as well as various spacing between the 
toxboxes (110, 183, 185).  
As linoleic acid was shown earlier to decrease promoter activity for all of these ToxT-
activated promoters, we determined whether linoleic acid also affected the binding affinity 
using EMSA with each promoter region as described above. For PctxAB, containing direct repeats, 
the Kd without linoleic acid is 4.44nM, and with linoleic acid is 10.1nM, indicating decreased 
binding affinity of ToxT (Figures 7A,B). As an example of an inverted repeat promoter, we chose 
to look at PtagA. Here, densitometry and binding curve analysis again revealed decreased 
binding affinity of ToxT for the promoter upon the addition of linoleic acid, with a Kd of 4.078nM 
without linoleic acid, and 27.8nM with linoleic acid (Figures 7C,D). Lastly, we examined ToxT 
binding to the single toxbox promoter of aldA. Figure 7E shows the autoradiograph of ToxT 
binding to PaldA with and without linoleic acid. The Kd once again was increased going from 
11.3nM without linoleic acid to 48.67nM with linoleic acid (Figure 7F). These data, along with 
the previously described decrease in promoter activity with the addition of linoleic acid as 
indicated by the β-galactosidase assays, suggest that linoleic acid decreases binding at each 
promoter regardless of toxbox configuration and spacing.  
Another negative ToxT effector, virstatin, acts differently than linoleic acid. The results 
above suggest a direct negative effect of linoleic acid on ToxT binding to DNA. We next 
examined whether this was also true for another negative ToxT regulator, virstatin. Previous 
studies suggested that virstatin negatively affects the ability of ToxT to dimerize (192). To begin, 
we looked at ToxT levels using Western blot analysis to compare V. cholerae grown with or 
without virstatin (Figure 1, lanes 6 and 7). The ToxT levels were unchanged, confirming that 
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ToxT production is not affected by virstatin. We then performed β-galactosidase assays on the 
previously described ToxT-regulated genes to assess the effects of virstatin (Figure 8). These 
data show decreased ToxT activity at all promoters except for aldA, where virstatin had no 
significant effect. Previous work had suggested that the aldA promoter was affected by virstatin 
(192). We then performed EMSAs to determine whether virstatin affected the DNA binding 
ability of ToxT at tcpA, ctxAB, and aldA, as representatives of the different toxbox 
configurations (Figure 9). Virstatin decreased binding at tcpA and ctxAB through analysis of the 
binding curve and Kd, (Figures 9A-D) but did not decrease ToxT binding at the aldA promoter 
even at a higher concentration of virstatin (Figure 9E). In fact, the Kd significantly decreased 
from 21.83nM to 11.79nM with the addition of virstatin, indicating a higher binding affinity of 
ToxT at the aldA promoter when virstatin is present (Figure 9F).   
DISCUSSION 
 The activation of virulence gene expression relies on the transcriptional activator, ToxT, 
active in mucus layer of the small intestine where V. cholerae colonizes. Previous studies have 
looked at the involvement of bile, UFAs, and virstatin on V. cholerae virulence gene expression 
and ToxT dimerization (182, 192, 193, 203-205). Most of this work with negative effectors has 
been done only on tcpA and ctxAB; here, in addition to these genes, we also look the effects of 
negative effectors on ToxT activity at aldA, acfA, acfD, tagA, and tcpI.  All ToxT-controlled 
promoters showed a decrease in expression in the presence of linoleic acid. Prior to entry into 
the mucus layer of epithelial cells and colonization, V. cholerae must pass through the lumen of 
the small intestine where high concentrations of bile and UFAs are present. Linoleic acid needs 
to be taken up by V. cholerae and enter the cytoplasm in order to directly interact with ToxT.  
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Here, we show that linoleic acid is able to enter the cell and that the majority of it enters the 
cytoplasm.  
Much work has been done previously on the effect of these negative effectors on 
virulence gene expression, but their direct effect on ToxT DNA binding affinity had not been 
previously assessed. It has been proposed that the mechanism of action for virstatin and UFAs 
is inhibition of ToxT dimerization (189, 192). The binding sites for ToxT, toxboxes, and their 
configurations have been extensively studied, but whether toxbox configuration factors into the 
inhibition of ToxT activity by linoleic acid had not been examined. Here we show that the 
decrease in binding affinity in response to linoleic acid can be seen at each ToxT-activated 
promoter that we examined, regardless of toxbox configuration. This suggests that linoleic acid 
has a general effect on DNA binding by ToxT monomers. Previous work strongly suggested that 
ToxT binds to DNA as a monomer (109, 110, 183) and that ToxT does not behave as a typical 
dimeric activator, such as AraC.  
 We also looked at virstatin and its method of action on ToxT. A previous study examined 
virulence gene promoter activity in the presence of virstatin; however, unlike this earlier study, 
the effect of virstatin in our hands was not as pronounced. We did observe that virstatin 
significantly decreased promoter activity to a lessened extent (Figure 8,(192)). While 
Shakhnovich et al. saw, at greatest, 20% promoter activity in the presence of virstatin at the 
aldA, acfA, and tcpI promoters, we observed a decrease, but not to that extent. Interestingly, 
we did not see any effect of virstatin on ToxT activation at the single toxbox, aldA promoter 
with the β-galactosidase assay (Figure 8). In this same regard, virstatin also did not have an 
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effect on the ability of ToxT to bind the aldA promoter (Figures 9E,F). In contrast, we did see a 
negative effect of linoleic acid at the aldA promoter on both ToxT-dependent virulence gene 
promoter activity (Figure 4) and ToxT binding affinity, where the Kd increased from 11.25nM to 
48.67nM (Figures 7E,F).  
These data suggest that virstatin and linoleic acid, although both negative effectors of 
virulence, do not have the same mechanism for downregulating gene expression. Another 
study performed bacterial two-hybrid assays to look at the effect of various UFAs on 
dimerization and the data suggest another UFA, oleic acid, does affect ToxT dimerization (204). 
However, linoleic acid was not tested and this study was done using only the NTD of ToxT 
instead of intact, full-length ToxT, whose dimerization has never been experimentally observed, 
at least in published reports. More testing using full-length ToxT in V. cholerae with this two-
hybrid system in the presence of linoleic acid would confirm whether or not linoleic acid is 
involved in dimerization. As there was reduced binding of ToxT at the aldA promoter, it is likely 
that linoleic acid changes the structural conformation of ToxT, leading to inhibited DNA binding. 
This will be further explored in Chapter Two of this dissertation. 
 Understanding the effect of host signals on bacterial pathogenesis is useful for complete 
understanding of the V. cholerae virulence cascade, as many host signals are used by the 
bacteria to sense the appropriate location in which virulence gene transcription should be 
initiated. When passing through the small intestine, V. cholerae encounters many different 
chemical signals, such as bile and bicarbonate, which either inhibit or activate ToxT-dependent 
gene transcription. Bile and its UFA components are at high concentrations in the duodenal 
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lumen, in which ToxT is inactive (191, 204, 205, 215). Once the mucus layer is penetrated, UFA 
concentration decreases, while the bicarbonate concentration increases.  At this point, along 
the epithelial surface, ToxT becomes active and V. cholerae can colonize.  UFAs such as linoleic 
acid likely keep ToxT in a form unable to bind tightly to DNA in the lumen, because production 
of TCP would lead to bacterial aggregation and colonization of the epithelial surface would 
become impossible. In this model, V. cholerae is able to use both negative and positive 
effectors of virulence in order to colonize in its ideal niche.  Our findings here show a direct 
effect of linoleic acid on ToxT, giving useful insight into the mechanisms of ToxT gene 
regulation. 
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FIGURE 1. Effect of linoleic acid on PtoxT::lacZ and ToxT expression. (A). Light gray bars, wild-
type V. cholerae grown without linoleic acid; dark gray bars, wild-type V. cholerae grown with 
64µM linoleic acid. Statistical significance was determined by Student's t test. (B). Effect of 
linoleic acid and virstatin on ToxT protein levels. V. cholerae was grown under virulence 
inducing conditions (LB pH 6.5, 30°C, aeration) with DMSO, linoleic acid or virstatin (lanes 4, 5, 
6). Purified full length ToxT-6His migrates to ~32kDa (lane 2) and a ΔtoxT strain shows no band 
(lane 3) were used as controls. Samples were normalized by OD600. The Western blot was 
probed with anti-ToxT antibody. This is representative of three separate experiments. 
  
a) b) 
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FIGURE 2. C14-radiolabeled linoleic acid is taken up by V. cholerae. Classical strain O395 cells 
were grown under virulence-inducing conditions for two hours and then the radiolabeled 
linoleic acid was added at time 0 and analyzed at times 5, 15, and 30 minutes post-addition, 
measured as CPM per optical density unit at 600nm.  The equation of best fit is y = 3421.3x + 
30974 and an R2-value of .969 
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FIGURE 3. C14-radiolabeled linoleic acid is able to enter the cell and enter the cytoplasm. After a 
2-hour subculture in virulence-inducing conditions, linoleic acid was added to the culture and 
allowed to sit for one hour.  After one hour, V. cholerae was fractionated into an envelope and 
cytoplasmic portion by multiple freeze-thaw cycles. There is significantly more linoleic acid in 
the cytoplasmic portion as compared to the envelope portion. Error bars represent +/- standard 
error mean and statistical significance was determined by Student's t test, *, p<.05   
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FIGURE 4. The negative effect of linoleic acid on various ToxT-activated promoters. Cultures 
were grown under virulence-inducing conditions with or without 160μM linoleic acid. β-
galactosidase activity produced from plasmid-borne virulence gene promoter fusion constructs 
in either wild-type or isogenic ΔtoxT. Statistical significance determined using Student’s t-test 
(*, p < 0.005; **, p<.0005). Error bars represent +/- standard error mean. 
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FIGURE 5. qRT-PCR data of tcpA and aldA comparing cultures grown with and without linoleic 
acid. Both transcripts were expressed less with the addition of linoleic acid. However there is a 
greater effect of linoleic acid on tcpA as compared to aldA. Data shown as the negative fold 
change of the inverse of the 2-ΔΔCT value. Statistical significance determined using Student’s t-
test (*, p<.05; **, p<.005).  
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FIGURE 6. Linoleic acid decreases binding affinity of MBP-ToxT to PtcpA. MBP-ToxT binding to 
PtcpA was analyzed using EMSA. (A) Binding reactions between MBP-ToxT and PtcpA in lanes 1-7 
were conducted in the absence of linoleic acid. Lanes 8-14 were incubated in the presence of 
32μM linoleic acid. Lanes 1 and 8 contained PtcpA DNA in the absence of MBP-ToxT. Subsequent 
lanes contained a titration of MBP-ToxT with concentrations labeled in the figure. (B) Binding 
curve for the autoradiograph shown in (A). Densitometry of autoradiograph was performed 
with ImageJ software. Circles represent percent PtcpA bound by MBP-ToxT in the absence of 
linoleic acid. Solid line corresponds to the binding curve for MBP-ToxT. Squares and dashed line 
represent percent bound and binding curve, respectively, in the presence of linoleic acid. (C) 
Autoradiograph of EMSA showing titration of MBP-CRP bound to PtcpP  with DMSO (Lanes 1-7) 
and linoleic acid (Lanes 8-14). (D) Binding curves with and without linoleic acid with Kd. 
Autoradiographs of EMSAs presented are representative of three or more independent 
experiments. Kd for each condition is inset and significant difference between the best-fit values 
of each data set is denoted by * (p< 0.0001).  
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FIGURE 7. Linoleic acid decreases binding affinity of MBP-ToxT at other virulence promoters. In 
all radiographs, binding reactions in lanes 1-7 are with DMSO only, while lanes 8-14 are in the 
presence of 32μM linoleic acid. (A), (C), (E) are autoradiographs showing MBP-ToxT binding at 
Pctx, PtagA, and PaldA respectively. (B), (D), (F) are the binding curves corresponding to each 
autograph: Pctx, PtagA, and PaldA respectively. All autoradiographs and binding curves are 
representative of at least three separate experiments. Kd for each condition is inset and 
significant difference between the best-fit values of each data set is denoted by * (p< 0.0001). 
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FIGURE 8. The effect of virstatin on ToxT-regulated virulence gene promoters. Cultures were 
grown under virulence-inducing conditions with and without virstatin. Promoter activity with 
and without 100μM was compared, and at all promoters except for aldA, virstatin caused a 
significant decrease in promoter activity. Statistical significance determined using Student’s t-
test (**, p<.005; ***, p<.0005).  
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FIGURE 9. Virstatin decreases binding affinity of MBP –ToxT at PtcpA and Pctx, but not at PaldA. In 
all radiographs, binding reactions in lanes 1-7 are with DMSO only, while lanes 8-14 are in the 
presence of virstatin. 50µM virstatin was used for (A) and (C) and 100µM for (E). (A), (C), (E) are 
autoradiographs showing MBP-ToxT binding at PtcpA, Pctx, and PaldA respectively. (B), (D), (F) are 
the binding curves corresponding to each autograph: PtcpA, Pctx, and PaldA respectively. All 
autoradiographs and binding curves are representative of at least three separate experiments. 
Kd for each condition is inset and significant difference between the best-fit values of each data 
set is denoted by * (p< 0.0005). 
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CHAPTER TWO 
A small unstructured region in Vibrio cholerae ToxT mediates the response to negative effectors  
ABSTRACT 
V. cholerae is the causative agent of the severe diarrheal disease cholera. A complex 
network of transcriptional and post-transcriptional regulators controls production of the 
virulence factors that are required for human disease. ToxT is the transcription regulator that 
directly controls the production of the two major virulence factors: toxin co-regulated pilus 
(TCP) and cholera toxin (CT). The solved crystal structure of ToxT revealed an unstructured 
region in the N-terminal domain between residues 100 and 110. This region and the 
surrounding amino acids have been previously implicated in ToxT proteolysis, resistance to 
inhibition of virulence induction by negative effectors, and ToxT dimerization. To better 
characterize this region, site-directed mutagenesis was performed to assess the effects of bile 
and its unsaturated fatty acid (UFA) components on ToxT sensitivity. This analysis identified 
specific mutations within this unstructured region that limit the inhibition of virulence gene 
activation by bile and unsaturated fatty acids. These results suggest that a small unstructured 
region in the ToxT N-terminal domain is involved in virulence gene regulation and response to 
human host signals. 
INTRODUCTION 
V. cholerae is the etiological agent of the severe diarrheal disease, cholera. Cholera 
disease is characterized by extreme water loss and dehydration due to diarrhea, and if left 
untreated can result in death. The bacteria are usually ingested through contaminated food or 
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water and colonize the upper small intestine (44). When the V. cholerae bacterium is in the 
optimal environment within the intestine, it begins producing the major virulence factors 
responsible for causing disease: cholera toxin (CT) and toxin co-regulated pilus (TCP) (100, 101, 
198). CT is an ADP-ribosylating toxin composed of five binding B subunits and one enzymatic A 
subunit (216). After binding the GM1 ganglioside via the B subunits, the A subunit is 
translocated into the intestinal epithelial cell, where it modifies Gsα1, leading to aberrant 
secretion of chloride, water, and other electrolytes (8). TCP is a type IV bundle-forming pilus 
responsible for bacteria-bacteria interactions that result in microcolony formation during 
intestinal colonization (99, 101, 217). 
TCP and CT are produced via a virulence regulatory cascade known as the ToxR regulon. 
Expression of CT and TCP is directly activated by the major virulence transcription regulator, 
ToxT (104, 133). ToxT binds “toxbox” motifs in the promoters of ctxAB and tcpA, as well as in 
the promoters of other accessory virulence factors, such as acfA, acfD, tagA, aldA, and tcpI, and 
small regulatory RNAs tarA and tarB, resulting in expression of these genes under appropriate 
conditions (109, 110, 113, 114, 133, 134, 183, 196). ToxT is a 276 amino acid protein that is part 
of the AraC/XylS family of transcription regulators (180). ToxT consists of two domains, the N-
terminal domain (1-160) (NTD) and the C-terminal domain (170-276) (CTD), separated by a 
short linker (161-169) (182). The CTD comprises the DNA-binding domain, consisting of two 
helix-turn-helix motifs, which has sequence similarity with the AraC/XylS family (181). The NTD 
shares no significant sequence similarity with any other protein, but shares secondary 
structural similarity with AraC (182) despite having only 14% identity at the amino acid level. 
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  Transcription of toxT is initially activated by both TcpP/H and ToxR/S (104, 135-137). 
After ToxT protein is present, it can produce more of itself independently of TcpP/H and ToxR/S 
by binding to the promoter of tcpA and activating transcription of a long, polycistronic mRNA 
containing toxT (134, 136). Proteolysis of ToxT is required to break this auto-regulatory loop 
and completely shut off virulence gene expression prior to escape from the host (218).  A region 
of the ToxT NTD between amino acids 100-109 was found to be required for proteolysis of ToxT 
(218). This region was not resolved in the ToxT crystal structure, indicating the absence of a 
fixed structure, at least in ToxT crystals (182). 
Activation of ToxT-dependent promoters is further regulated by effector molecules that 
act on ToxT. ToxT activity is inhibited by bile and, to a greater extent, the unsaturated fatty acid 
(UFA) components of bile, including oleic, linoleic, and arachidonic acid (204, 205). The ToxT 
crystal structure contained a buried 16-carbon fatty acid, palmitoleic acid, which was shown to 
decrease binding of ToxT to the tcpA promoter when added exogenously (182). Another 
inhibitor of ToxT, virstatin, decreases ToxT activation of ctxAB and tcpA by presumably 
inhibiting ToxT dimerization (192, 193). On the other hand, ToxT activity is enhanced by 
bicarbonate, which is abundant within the upper small intestine where V. cholerae colonizes 
(202). Given their high concentrations in the upper small intestine, bile and bicarbonate are 
likely to be in vivo effectors used by V. cholerae to determine the optimal location for 
colonization. 
In the solved ToxT crystal structure, a region between amino acids 100-109 was not 
visible, indicating that it lacked a consistent structure, at least in the context of the crystal. This 
56 
 
 
 
unstructured region was shown to contain the site critical for proteolysis (218), and, together 
with the surrounding amino acids, has also been implicated in responding to bile, unsaturated 
fatty acids (UFAs), and virstatin (189, 190, 210). Due to its importance for ToxT proteolysis and 
sensing of ToxT inhibitory substances, we performed site-directed mutagenesis on this 
unstructured region and the surrounding amino acids to identify specific amino acid changes 
that alter ToxT function. Mutational analysis of amino acids 100-110 confirmed that this region 
is important for control of ToxT proteolysis. We have further identified specific mutations that 
prevent the ToxT effectors bile and its UFA components from affecting ToxT activity. These 
results suggest that the unstructured region in the ToxT NTD plays a central role in control of V. 
cholerae virulence by impacting ToxT activity at multiple levels. 
MATERIALS AND METHODS 
Bacterial Strains and Growth Conditions. Escherichia coli JM101 was used for cloning. 
All strains were maintained at -70°C in LB containing 20% glycerol. For determination of 
response to negative effectors, overnight cultures of classical O395 V. cholerae were diluted 
1:40 into LB pH 6.5 in the presence or absence of 0.05% sodium choleate (Sigma-Aldrich) as a 
substitute for crude bile and 32 μM linoleic acid (Acros Organics). Cultures were grown shaking 
for 3 hours at 30°C and analyzed. Induction of protein expression from pMAL-c2e derivatives in 
all of these conditions was done using a final concentration of 25μM isopropyl-β-D-
thiogalactopyranoside (IPTG).  
Plasmid and strain construction. Construction of site-directed ToxT mutants was done 
using splicing by overlap extension PCR (219). For cloning C-terminal His-tagged toxT into 
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pBAD33, outside primers BP22 and BP195 (218) were paired with inside primers containing 
desired mutations using V. cholerae O395 toxT as a template. PCR products were inserted into 
pBAD33 using restriction enzymes XbaI and PstI. For cloning MBP-ToxT, outside primers BP171 
and BP172 (218) were paired with inside primers and PCR products were inserted into the 
pMAL-c2e vector using restriction enzymes KpnI and PstI. pBAD33 and pMAL-c2e derivatives 
were electroporated into a previously constructed V. cholerae classical biotype strain O395 
∆toxt mutant with a chromosomal tcpA::lacZ fusion (202). 
β-galactosidase assays. Cells were grown under the appropriate conditions and β-
galactosidase activity was measured and expressed in Miller units as previously described (202, 
212, 218, 220). 
Protein purification and electrophoretic mobility shift assays (EMSA). Protein 
purification and EMSAs were performed as previously described (214). Maltose-binding protein 
(MBP) fusions were purified from E. coli BL21(DE3) with plasmid pMAL-c2e containing either 
MBP-ToxT WT or MBP-ToxT N106F. DNA probes for EMSA were produced by PCR of plasmid 
pTL61t containing PtcpA. Binding reactions were performed in 30uL total volume containing 10 
μg/mL salmon sperm DNA, 10 mM Tris-acetate (pH 7.4), 1 mM Potassium EDTA (pH 7.0), 100 
mM KCl, 1 mM dithiothreitol (DTT), 0.3 mg/mL bovine serum albumin (BSA) and 10% glycerol, 
along with titrations of MBP-ToxT WT or N106F. Binding reactions were performed in the 
presence of 32 μM linoleic acid for 30 minutes at 37°C, and run through a 6% polyacrylamide 
gel at 4°C. Binding reactions for comparison to linoleic acid reactions contained 3.33% DMSO. 
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Binding curve analysis. Autoradiographs were analyzed using ImageJ software (NIH) as 
previously described (data submitted for publication). Briefly, the percent of labeled DNA 
bound by MBP-ToxT WT or N106F was determined for each lane and Graphpad Prism 5 
software was used for curve fitting to the equation %Bound=Bmax*[Protein]h/(Kd
h + [Protein]h) 
with Bmax constraint set to 100. The Kd for each condition was calculated and significance of Kd 
between conditions was determined.  
RESULTS 
Identification of ToxT residues involved in responding to natural negative effectors, 
bile and linoleic acid. The crystal structure of ToxT revealed a small, unstructured region in the 
NTD of the protein (182). This region, as well as the surrounding amino acids, has been 
implicated in ToxT proteolysis, resistance to negative effectors of ToxT activity, and 
dimerization (190-193, 215, 218). To further characterize this region in regard to these roles, we 
performed site-directed alanine mutagenesis of ToxT amino acids 100-110, shown in Figure 10. 
The unstructured region of ToxT has previously been shown to have residues that are required 
for normal response of ToxT to bile and UFAs (189, 191). Bile and UFAs decrease the ability of 
ToxT to activate transcription of virulence genes (204, 205). Two ToxT mutations, M103A and 
N106A, have previously been described as insensitive to bile and UFAs (189). We tested strains 
carrying these ToxT mutations, as well as strains carrying other alanine substitutions in the 
unstructured region, to determine whether their response to these negative ToxT effectors was 
altered. Overexpression of ToxT eliminates the effect of bile and linoleic acid on ToxT activity. 
Therefore, we chose to use the IPTG-inducible expression vector pMAL-c2e in place of 
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arabinose-inducible pBAD33 to easily decrease the overall production of ToxT, and to facilitate 
protein purification for downstream applications. Previous work that used MBP-ToxT fusions 
showed no significant difference in activity as compared to untagged ToxT (205). As a further 
control for any effect the MBP tag may have had on ToxT activity, we also performed 
experiments with untagged ToxT mutants of interest and found that they respond to effector 
molecules similarly to MBP fusions using the pMAL-c2e vector (data not shown). The MBP-ToxT 
mutants were induced from pMAL-c2e in a ΔtoxT derivative of classical biotype V. cholerae 
strain O395 containing a chromosomal tcpA::lacZ transcriptional fusion. Induction of tcpA 
transcription in the presence and absence of negative effectors was measured by β-
galactosidase reporter assay and used as a metric for ToxT activity. The fold change upon 
addition of effector molecules was calculated for each individual experiment. The mean fold 
change for each mutant was determined and will be referred to as ToxT’s response to effectors. 
Significance of the fold change of each ToxT mutant compared to the fold change of WT ToxT in 
response to negative effectors was determined using a Student’s t-test. 
Figure 11A shows the activity and response of the ToxT mutants to 0.05% sodium 
choleate, a crude derivative of bile. 0.05% sodium choleate was the lowest concentration that 
still decreased ToxT activity in titration experiments (data not shown). Alanine mutations to 
amino acids 100-104, 107, and 108 caused reductions in overall activity of ToxT in the presence 
and absence of bile as compared to WT MBP-ToxT. These results agree with previous reports 
that mutations at these residues reduce activation of acfA::phoA (190). The L107A mutation 
completely eliminated tcpA::lacZ expression. Prior reports have suggested that this mutation 
inhibits ToxT dimerization and therefore inhibits ToxT activity (189, 190). Additionally, ToxT 
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R105A had higher overall activity compared to WT, as has been previously reported (190). The 
fold decrease in activation of tcpA::lacZ upon addition of bile was calculated for each mutant 
(Figure 11A). This analysis revealed ToxT mutations (G100A, D101A, I104A, Y108A, and E110A) 
that caused a greater sensitivity to the negative effect of bile. The M103A mutation did not 
affect the sensitivity of ToxT to bile as compared to WT, which was unexpected as this mutant 
reportedly had decreased sensitivity to bile when measuring CT and TCP production (189). 
However, a mutation at amino acid 106, which had been previously shown to decrease 
sensitivity to bile when measuring CT and TCP production (189) also decreased sensitivity to 
bile in our work. 
 The ability of these ToxT mutants to activate tcpA::lacZ in the presence or absence of 32 
μM linoleic acid was also assessed (Figure 11B). As was observed in the bile experiments, 
mutation to residues 100-104, 107, and 108 caused decreased overall transcriptional activity 
with and without added effector. Also, mutants D101A, M103A, I104A, and Y108A had 
increased sensitivity to linoleic acid, as we had observed with bile. Previous work suggested 
that the M103A ToxT mutant has diminished sensitivity to another UFA, palmitoleic acid (189). 
However, we observed increased sensitivity of M103A to the negative effector linoleic acid.  
Mutant N106A, which was previously reported to cause a reduced response to palmitoleic acid 
in terms of CT and TCP production (189), also exhibited decreased activation of tcpA::lacZ in the 
presence of linoleic acid, verifying the importance of this residue for the response to negative 
effectors. Interestingly, this mutant also showed decreased sensitivity for addition of bile as 
well as bicarbonate, a positive effector of ToxT, (data not shown). These results suggest that the 
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same ToxT residues within the unstructured region may be involved in both positive and 
negative effectors. 
Alternate substitutions in the ToxT unstructured region affect response bile and UFAs. 
The results described above show that alanine mutagenesis within the unstructured region of 
ToxT alters the protein’s sensitivity to bile and unsaturated fatty acids. Because amino acids 
mutated to alanine in the unstructured region showed reduced sensitivity to both bile/UFA and 
bicarbonate, we generated alternate substitutions of amino acids 105 (as it showed less 
sensitivity to bicarbonate, data not shown) and 106 to further investigate the role of these 
residues in ToxT function. We also made mutations to amino acid 107 because the L107A 
mutant was completely inactive and a previous report showed that mutation L107F had 
decreased response to bile (191). Finally, we made an alanine substitution of amino acid L114, 
which has been shown to cause insensitivity to the inhibitory effects of bile, UFAs, and virstatin 
and is located in close proximity to the 100-109 unstructured region (189, 193). ToxT mutants 
R105K, R105Q, R105F, N106S, N106F, L107F, L107S, L114A, and a double mutant R105A/N106A 
were tested using the β-galactosidase assay described above in bile/linoleic acid inhibiting 
conditions (Figures 12A,B). Fold change with addition of effectors was calculated for each 
mutant and compared to the fold change response of WT ToxT. 
Alternate substitutions at amino acid R105 generally exhibited higher than normal ToxT 
activity in the absence of effector molecules, similar to what was observed after mutation to 
alanine. ToxT R105Q had increased response to the negative effector bile, while ToxT R105F 
exhibited a decreased response to bile (Figure 12A). On the other hand, ToxT R105K exhibited 
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increased sensitivity to linoleic acid (Figure 12B). The increased sensitivity to negative effectors 
of the R105K and R105Q mutants may be due to a conformational change in the protein that 
increases accessibility of the negative effector binding sites. ToxT L107F, which has previously 
been reported as having decreased response to bile and UFAs (191), had increased response to 
both negative effectors compared to WT. ToxT L107S was similar to L107A in having inactivity. 
ToxT N106S had a response to bile similar to WT, while the double mutant R105A/N106A had 
decreased sensitivity to bile, presumably due to the N106A mutation (Figure 12A). The N106S 
mutation caused an increase in response to linoleic acid, but the double R105A/N106A mutant 
displayed reduced sensitivity to linoleic acid (Figure 12B). L114A was insensitive to bile and 
UFAs as previously described (189). Another mutation, N106F, revealed complete insensitivity 
to the negative effectors, bile and linoleic acid. This is a novel mutation that exhibits greatly 
decreased response to negative effectors.  
Change in binding affinity of ToxT N106F is reduced in presence of the linoleic acid. 
Previous work has suggested that palmitoleic acid decreases the ability of ToxT to bind to PtcpA 
(182). Additionally, we have shown that linoleic acid decreases the binding affinity of ToxT to 
virulence gene promoters regardless of toxbox orientation (Chapter One). To assess the ability 
of linoleic acid to alter the binding affinity of ToxT N106F to PtcpA, we subjected WT MBP-ToxT 
and the N106F derivative to electrophoretic mobility shift assays (EMSA). Experiments were 
designed to determine the equilibrium binding affinity of ToxT for the major virulence gene 
promoter, PtcpA, in the absence and presence of effector. DNA was added to binding reactions at 
a concentration below the estimated Kd along with a titration of MBP-ToxT.  
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A representative autoradiograph containing the titration of WT MBP-ToxT binding in the 
absence (Lanes 1-6) and presence of 32 μM linoleic acid (Lanes 7-12) is shown in Figure 13A. 
Binding reactions in the absence of linoleic acid contained a volume control of DMSO. The 
binding curves for each condition were generated using Graphpad Prism 5 software and the 
equation %Bound=Bmax*[MBP-ToxT]h/(Kdh + [MBP-ToxT]h). From this equation, the equilibrium 
binding affinity, Kd, was determined and significance was calculated (Figure 13B). The Kd of WT 
ToxT for PtcpA was increased with linoleic acid, corresponding to a decrease in binding affinity. 
The MBP-ToxT N106F mutant was also assessed for changes in Kd in the presence of linoleic 
acid. The EMSA and resulting binding curve for reactions containing linoleic acid revealed no 
significant change in Kd when compared to the DMSO control (Figures 13C,D). The lack of 
change in binding affinity of ToxT N106F with the addition of these ToxT effector molecules 
correlates with the transcriptional reporter assays described above (Figures 12,13D), providing 
a direct link between changes in DNA binding and transcriptional activation. 
DISCUSSION 
ToxT is the major transcription activator that induces CT and TCP production and thus is 
responsible for initiating cholera disease. It has previously been shown that amino acids in the 
region of 100-110 of ToxT are important for the response to negative effector molecules and 
dimerization (189-193). Also, this region was required for ToxT proteolysis (218). Interestingly, 
this region was not visible in the solved ToxT structure due to the absence of a fixed structure in 
ToxT crystals (182). We discovered amino acids important for the response of ToxT to bile and 
linoleic acid including N106A, R105A/N106A, N106F, and L114A, which all showed decreased 
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sensitivity to the effector when mutated. These same amino acid substitutions were also 
important in the response to the positive effector bicarbonate (data not shown). Most 
mutations to amino acid 105 had no effect on reducing the response to bile and linoleic acid, 
but have been shown to have reduced sensitivity to bicarbonate (data not shown). Additionally, 
effector-insensitive ToxT N106F demonstrated no change in binding affinity to PtcpA in response 
to UFA and bicarbonate.  
The negative effectors of ToxT activity, bile, UFAs, and virstatin, have been implicated in 
reducing dimerization of ToxT monomers, leading to reduced overall activity (189, 192). We 
hypothesize that negative effector binding forces ToxT into an inactive conformation that could 
be due to decreased interaction between ToxT monomers through the unstructured region, 
similar to has been previously proposed based on the ToxT crystal structure (182). The 
unstructured region of ToxT is a likely candidate for effector molecule binding due to its 
importance in the response to negative and positive effectors, solvent accessibility (182) for 
on/off binding, and its disorder in the crystal structure. Unstructured regions in crystal 
structures are often disordered due to the lack of a stabilizing molecule (221), which could also 
be the case with ToxT. It is unlikely that UFAs directly bind the unstructured region of ToxT, as 
mutations in the region do not reverse the proteolytic blockade by linoleic acid, but it is 
hypothesized that the positive effector bicarbonate could bind in this region. Previous findings 
in our lab revealed that the addition of linoleic acid blocked proteolysis of ToxT, but the UFA-
insensitive ToxT N106F did not reverse the effect of linoleic acid on ToxT proteolysis (data not 
shown). Therefore, we conclude that amino acid N106 is not part of a binding site for UFAs, 
agreeing with results from (182). The unstructured region is likely to be important for the 
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change in ToxT structure, mediated by linoleic acid binding, which results in lower DNA binding 
affinity.  
We have previously introduced a model wherein ToxT becomes activated by 
bicarbonate as the concentration of bicarbonate increases when V. cholerae enters the mucus 
layer of the small intestine (202). This model posits that ToxT is in an inactive form in the lumen 
of the intestine due to a lower local concentration of bicarbonate. The model was expanded in 
(222), where bile/UFAs in the lumen of the intestine inactivate ToxT, and are replaced by 
bicarbonate as the bacterium moves closer to the mucus/epithelial layer. Using this model of 
ToxT-dependent virulence in the host, it is plausible that the inactive state of ToxT with UFA 
bound can be converted to the active state in the presence of enough bicarbonate, even 
though the effectors may not bind in the same region. After ToxT is produced and V. cholerae is 
in the lumen of the intestine, ToxT must remain intact but inactive so that CT and TCP are not 
produced prematurely in infection. UFAs in bile provide a mechanism for ToxT inactivity in the 
lumen and also protect ToxT from proteolysis. As the bacteria encounter higher concentrations 
of bicarbonate and lower concentrations of UFA closer to the epithelial surface, bicarbonate 
binds and converts ToxT to its active conformation.  
In this model, shown in Figure 14, we propose that when ToxT is produced under 
virulence inducing conditions it is in fluctuation between an active and inactive conformation in 
the absence of effector molecules. This fluctuation leads to mid-level virulence promoter 
activity. In the presence of negative effector molecules, ToxT becomes locked into an inactive 
conformation, resulting in low virulence gene promoter activity. In this conformation, it is 
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proposed that the NTD and CTD are pulled together by the effector molecule (182), and we add 
that this conformation impedes access to the unstructured region by the ToxT protease. This 
conformation could also inhibit ToxT dimerization. Alternatively, in the presence of the positive 
effector molecule bicarbonate, ToxT is locked into an active conformation, causing the highest 
virulence gene promoter activity. We propose that the active conformation of ToxT has an 
exposed unstructured region that leads to a high degree of proteolysis. 
In summary, we determined that an unstructured region in the NTD mediates the 
response of ToxT to negative effectors present in the intestine. This unstructured region plays a 
role in the response of ToxT to environmental signals and has implications for the temporal and 
spatial regulation of virulence factor production in the host 
Work performed in the chapter is all my own; however, most of the text is from a 
manuscript with Joshua Thomson.  
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FIGURE 10. Linear representation of ToxT domain orientation and mutagenesis sites. Amino 
acids located in the unstructured region (UR) of ToxT between amino acids 100-110 were 
mutated to alanine for initial analysis of region. N-terminal domain (NTD) located between 100-
160; Linker (L) located between 160-169; C-terminal domain (CTD) between 170-276. Helix-
turn-helix domains 1 and 2 (HTH1,HTH2) located within the CTD.  
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FIGURE 11. Effect of MBP-ToxT alanine mutagenesis in response to negative effectors, bile and linoleic 
acid. V. cholerae O395 ΔtoxT mutant with plasmid-borne WT or MBP-ToxT mutants were grown under 
virulence-inducing conditions with or without the addition of negative effectors for 3 hours. (Top) Light 
gray bars, V. cholerae grown (A) without bile or (B) with dimethyl sulfoxide (DMSO) alone; dark gray 
bars, grown with (A) 0.05% bile or (B) 32μM linoleic acid dissolved in DMSO. β-galactosidase produced 
from chromosomal tcpA::lacZ in classical strain O395 ΔtoxT. Statistical significance of ToxT mutant 
activation of tcpA::lacZ in each condition compared to WT ToxT activation of tcpA::lacZ in the same 
condition was calculated using Student’s t-test. Statistical significance of activation by ToxT mutants 
without effector denoted by *, with effector by + (*, +,p<0.05). (Bottom) Mean fold-decrease in 
activation of tcpA::lacZ upon addition of (A) 0.05% Bile or (B) 32μM linoleic acid for each ToxT mutant. 
Statistical significance of fold change MBP-ToxT mutant compared to WT MBP-Toxt was determined by 
Student’s t-test (*,P<0.05; **,P<0.01). Horizontal dashed line represents fold-change with addition of 
effector of WT ToxT. ToxT mutants above line have increased sensitivity to effector, while below line 
represents decreased sensitivity to effector. WT, wild type. Error bars represent +/- standard error of 
the mean (SEM). 
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FIGURE 12. Alternate substitutions of unstructured region of ToxT affect response to negative 
effectors. V. cholerae O395 ΔtoxT mutant with plasmid-borne WT or mutant MBP-ToxT were 
grown in the absence and presence of negative effectors. (Top) (A) β-galactosidase produced in 
absence and presence of 0.05% bile. (B) β-galactosidase produced in dimethyl sulfoxide (DMSO) 
or 32μM linoleic acid dissolved in DMSO. β-galactosidase produced from chromosomal 
tcpA::lacZ in classical strain O395 ΔtoxT. Statistical significance of ToxT mutant activation of 
tcpA::lacZ in each condition compared to WT ToxT activation of tcpA::lacZ in the same condition 
was calculated using Student’s t-test. Statistical significance of activation by ToxT mutants 
without effector denoted by *, with effector by + (*, +,P<0.05). (Bottom) Mean fold-decrease in 
activation of tcpA::lacZ upon addition of effector shown for each ToxT mutant. Statistical 
significance of fold change MBP-ToxT mutant compared to WT MBP-Toxt was determined by 
Student’s t-test (*,P<0.05; **P,<0.01). Horizontal dashed line represents fold-change with 
addition of effector of WT ToxT. ToxT mutants above line have increased sensitivity to effector, 
while below line represents decreased sensitivity to effector. WT, wild type. Error bars 
represent +/- standard error of the mean (SEM). 
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FIGURE 13. MBP-ToxT N106F has no change in binding affinity to PtcpA after addition of linoleic 
acid. MBP-ToxT WT and N106F binding to PtcpA was analyzed using EMSA. Autoradiographs of 
EMSAs presented are representative of three or more independent experiments. (Left) Binding 
reactions between (A) MBP-ToxT WT or (B) MBP-ToxT N106F and PtcpA in lanes 1-7 took place 
with the addition of DMSO. Lanes 8-14 were incubated in the presence of 32 μM linoleic acid. 
Lanes 1 and 8 contained PtcpA DNA in the absence of MBP-ToxT. Subsequent lanes contained a 
titration of MBP-ToxT with concentrations labeled in the figure. (Right) Binding curve for the 
autoradiograph shown to the left. Densitometry of autoradiograph was performed with ImageJ 
software. Circles represent percent PtcpA bound by MBP-ToxT in the absence of linoleic acid. 
Solid line corresponds to the binding curve for MBP-ToxT to PtcpA determined by the equation 
%Bound=Bmax*[Protein]h/(Kdh + [Protein]h) with Bmax constraint set to 100 using Graphpad 
Prism 5 software. Squares and dashed line represent percent bound and binding curve, 
respectively, in the presence of linoleic acid. Kd for each condition is inset and significant 
difference between the best-fit values of each data set is denoted by * (P < 0.00025). 
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FIGURE 14. Model for effector control of ToxT activity. In the absence of effector molecules, 
there is mid-level transcriptional activation of ToxT and it is in fluctuation between inactive and 
active conformations. When bicarbonate is present, ToxT is at high-level transcriptional 
activation. The ToxT conformation has increased binding affinity to toxboxes but also leaves the 
unstructured region (UR) (proposed to contain a proteolytic cleavage site) accessible by 
protease. This conformation resembles ToxT mutants N106F and L114A. Conversely, when 
negative effectors are present, ToxT is in an inactive conformation where it has low-level 
transcriptional activation. The UR is inaccessible in this conformation, so the site is inaccessible 
to protease.  
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CHAPTER THREE 
The use of conjugated linoleic acid as a potential cholera therapeutic 
ABSTRACT 
The severe diarrheal disease cholera is currently endemic in over 50 countries. Although 
much work has been done to develop effective vaccines against the causative agent, V. 
cholerae, these vaccines are currently only effective for very limited amounts of time and do 
not offer complete protection. Linoleic acid has been shown to be an effective negative 
regulator of V. cholerae virulence, not by killing the bacteria as an antibiotic would, but instead 
by acting on the major virulence transcriptional regulator protein, ToxT, to inhibit virulence 
gene expression. ToxT activates transcription of the two major virulence factors required for 
disease, cholera toxin (CT) and toxin co-regulated pilus (TCP). A conjugated form of linoleic acid 
(CLA) is currently sold on the market as a dietary supplement to aid in weight loss, is considered 
safe by the US Food and Drug Administration, and is relatively inexpensive. This study examines 
using CLA as a new potential prophylactic or as a therapy to reduce CT and TCP production, 
which, in turn, would decrease disease duration and intensity.  
INTRODUCTION 
Cholera is a devastating diarrheal disease that affects between 1.4-4.3 million people 
each year causing between 28,000-142,000 deaths (14, 15). The disease is characterized by 
severe dehydration that leads to organ shutdown and eventual death if not treated rapidly. It is 
caused by the gram-negative curved rod V. cholerae when a person ingests large quantities of 
contaminated water or raw shellfish colonized with V. cholerae. Current treatment is oral 
rehydration solution as specified by the World Health Organization, containing various salts and 
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glucose to rehydrate as well as replenish electrolytes (3). Without treatment, survival is 
approximately 50%, but rehydration with ORS bring survival to greater than 99% (8). Antibiotics 
are a treatment option; however their use is limited. By the onset of cholera symptoms, the 
bacteria are already being shed back into the environment, but antibiotics can act to slightly 
shorten the duration of disease symptoms. As only 25% of people show symptoms when 
infected with V. cholerae, the other 75% are still able to shed bacteria into the environment, 
potentially for another person to ingest (6, 7).  
V. cholerae is classified based on the O antigen of its lipopolysaccharide, and though 
there are over 200 serogroups in the environment only one serogroup, O1, has been associated 
with pandemics (1, 8, 16). The O1 serogroup can be divided into two biotypes: classical and El 
Tor. V. cholerae has caused seven pandemics, and of these, the classical biotype was the 
causative agent of the first six, while the El Tor biotype caused the most recent, ongoing 
seventh pandemic (8, 16). The classical biotype also causes a more severe disease, but El Tor is 
thought to survive better in the environment, although the reasons for this are not understood 
(16, 17). O139, another serogroup, emerged in the early 1990s as being involved in outbreaks 
(18-21). As such, some refer to these outbreaks as an eighth pandemic (18). 
Much work has been done on the development of effective vaccines. There are two oral 
vaccines currently available, each with questionable efficacy (28, 29). Neither vaccine is licensed 
in the United States due to their lack of complete and long-term protection. The first vaccine, 
Dukoral, consists of killed whole V. cholerae cells of both biotypes of serogroup O1 and the B 
subunit of CT. It has had very different success in field trials, including a trial in Peru involving 
over 17,000 people where the vaccine only offered 15% protection in persons aged six and up 
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after one year of surveillance (223). The now preferred vaccine is called Shanchol and it is 
composed of both O1 and O139 serogroups. Disappointingly, this vaccine also showed only 45% 
protection in all age groups after one year (224, 225).  As over half the deaths due to cholera 
are in children under five (226), a vaccine that effective in small children is essential. Dukoral, 
actually offered negative protection in a field trial in Peru during the first year of surveillance, 
and Shanchol only offered 17% protection (223-225, 227). Clearly, more effective vaccines are 
necessary. 
In order to initiate disease, production of two virulence factors is necessary: CT and TCP. 
CT is an A-B5 toxin responsible for the profuse watery diarrhea, while TCP is necessary for host 
colonization. The genes encoding both of these virulence factors are both under control of the 
major transcriptional activator, ToxT (104, 132-134). V. cholerae encounters high 
concentrations of bile and its unsaturated fatty acid components, such as linoleic acid, in the 
small intestine before entering the mucosal layer where it is eventually able to colonize (42-44). 
In the presence of these negative ToxT effectors, V. cholerae expresses its motility genes, but its 
virulence inducing genes are not expressed, as ToxT is not active (40, 41).  
To activate the transcription of CT and TCP, ToxT binds to their respective promoters on 
binding sites known as toxboxes (183). Linoleic acid can decrease virulence gene expression by 
directly reducing the ability of ToxT to activate these promoters (Chapter 1). Currently, CLA is 
sold over the counter as a weight loss supplement aimed at inhibiting fat absorption. As it is 
relatively cheap and easily accessible, we propose that CLA could potentially be used as either a 
cholera prophylactic or as a therapy used in conjunction with oral rehydration to reduce disease 
length and intensity by reducing virulence gene production. As antibiotic resistance is becoming 
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a more and more concerning problem, using a therapy that can inhibit pathogenesis, but not 
bacterial survival, is becoming much more attractive. Here, we show that CLA is able to 
downregulate virulence gene expression by acting on ToxT. We also show the effect of CLA in 
two animal models: the infant mouse model, which measures the ability of V. cholerae to 
colonize and the rabbit ileal loop model, which is used to measure disease by looking at CT-
dependent fluid accumulation in a rabbit intestinal loop. 
   
MATERIALS AND METHODS 
V. cholerae strains and growth conditions. All V. cholerae strains used in the study are 
derived from classical biotype strain O395.  Strains were maintained in Luria Broth (LB) 
containing 20% glycerol and stored at -70°C. Overnight cultures were grown overnight at 37°C 
in LB and then subcultured 1:40 into LB pH 6.5 at 30°C for three hours for virulence inducing 
conditions in the presence or absence of 32 or 128µM CLA dissolved in DMSO, or in later 
experiments, 640µM of ME-CLA, or 32 µM of one of the three common isoforms of CLA: 
9E,11E-; 9Z,11E-; or 10E,12Z- (Sigma-Aldrich). V. cholerae strains were grown with antibiotic 
concentration of streptomycin at 100µg/mL. 
β-Galactosidase and CT assays. β-galactosidase activity was measured using the basic 
procedure of Miller (212). CT was detected in the culture supernatant by a GM1 enzyme-linked 
immunosorbent assay (ELISA) (228), using polyclonal anti-CT antibody (Sigma). Briefly, for both 
assays, bacteria were grown with or without CLA, CLA-ME or one the CLA isoforms for three 
hours under virulence-inducing conditions and then analyzed. DMSO was used as a solvent 
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control. A positive control assay for quantification of the level of CT in the samples was 
performed using purified CT (List Biological Laboratories). 
 Electrophoretic mobility shift assays (EMSA) and binding curve analysis. EMSAs were 
performed as previously described (214). Purified MBP-ToxT (described previously), was 
incubated with DNA probes made from the promoter sequence of interest that had previously 
been inserted into the plasmid pTL61T and labeled with γ-32P (Perkin-Elmer) by T4 
polynucleotide kinase (New England Biolabs). Binding reactions contained various amounts of 
MBP-ToxT with constant 10 µg/mL salmon sperm DNA, 10mM Tris-acetate (pH 7.4), 1mM 
Potassium EDTA (pH 7.0), 100mM KCl, 1mM dithiothreitol (DTT), 0.3mg/mL bovine serum 
albumin (BSA) and 10% glycerol in a volume of 30µL. To each reaction, a constant concentration 
of the labeled DNA probe was added. In reactions containing CLA, the final concentration was 
32µM for each reaction. All other reactions contained 3.33% (1μL in 30μL) of DMSO as a solvent 
control. Binding reactions were incubated for 30 minutes at 37°C and then loaded into a 6% 
polyacrylamide gel to be run at 4°C. Gels were dried for 1 hour and then analyzed by 
autoradiography. 
 Binding curve analysis.  Autoradiographs were analyzed using ImageJ software (NIH) as 
previously described. Kd values were determined for each binding curve and then the Kd for 
each condition were compared to each other using the extra sum of squares F test to 
determine if the two values were statistically different.  
Infant mouse colonization assays. 5 day old CD1 mouse pups were inoculated with 
approximately 106 V. cholerae strain C6706 (El Tor) by oral gavage in a total volume of 50 l. 
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CLA, if given, was administered at the time of initial gavage and boosted twice at hours 2 and 4 
post-infection. 20 hours post infection the pups were sacrificed, their intestines dissected and 
homogenized using a bead beater, and serial dilution of the intestinal homogenate were plated 
to enumerate V. cholerae. 
 Infant mouse colonization assays. Infant mouse assays were performed as previously 
described (114). Briefly, 5 days old CD1 mouse pups were inoculated with ~106 V. cholerae 
classical strain O395 in 50 l total volume, containing 0.5% Evans Blue as a tracer, by oral 
gavage. Mice treated with CLA were given either 5% or 10% CLA by volume in 10% Kolliphor 
RH40 or 10% Kollidon 25 as a carrier at the time of inoculation. These mice were also boosted 
with the indicated concentration of CLA at 3 hr and 6 hr post inoculation. At 20 hr post-
infection the mice were sacrificed, dissected, and intestines homogenized using a bead beater. 
Intestinal homogenates were serially diluted and plated on LB agar containing 100 g/ml 
streptomycin for the enumeration of colonizing V. cholerae. 
 Rabbit ileal loop assays. Fluid accumulation in rabbit ileal loops was performed as 
previously described (229). Briefly, 10 cm loops of small intestine were injected with 1 ml total 
volume containing approximately 106 V. cholerae strain C6706 (El Tor) and various amounts of 
CLA. A negative control loop was injected with 1 ml PBS. After 16 hours, the rabbits were 
sacrificed and their intestines dissected out. Fluid volume from each loop was measured and CT 
ELISA was performed to assess the mount of CT produced under each condition. 
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RESULTS 
CLA acts as a negative ToxT effector for activation of both TCP and CT. Our previous 
work showed that linoleic acid decreased ToxT activity, leading to a decrease in virulence gene 
expression (Chapter One). Here, we wanted to assess whether CLA would also exert negative 
activity on ToxT, as measured by PtcpA expression as well as CT production. This would confirm 
that CLA affects both major virulence factors in the classical biotype V. cholerae strain O395.  To 
begin, we used the highest concentration of CLA that did not affect bacterial growth, 128 µM. 
In the presence of CLA, there is a significant reduction in PtcpA activity when V. cholerae is grown 
under virulence-inducing conditions as compared to cultures grown in the same conditions, but 
in the absence of CLA (Figure 15A). We then wanted to confirm that CLA had a similar effect on 
the production of CT (Figure 15B).  After growing the bacteria for three hours under virulence-
inducing conditions, we looked at the supernatant to quantify the amount of secreted CT. CT 
production was also significantly reduced in the presence of CLA. Thus these results indicate 
that CLA works as expected to attenuate V. cholerae virulence gene expression in vitro 
The CLA used in the previous experiment is a mixture of cis- and trans-9,11- and -10,12-
linoleic acid. To look at the different effects of each isoform, we used the lowest concentration 
of the multi-isoform CLA that still had an effect on PtcpA expression, 32 µM. By using this 
concentration, it allowed us to more easily compare effects of each isoform to one another as 
more or less effective at decreasing PtcpA activity.  To begin, we looked at CLA-ME. This is made 
by the transesterification of CLA with methanol. This compound had no effect on promoter 
expression even at a concentration 20 times the amount we used of the other CLA forms, 
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indicating it is the fatty acid and not only its aliphatic chain that is involved in downregulation of 
ToxT activity, and thus virulence gene expression  (Figure 16).  Next, we looked at the three 
most common isoforms of CLA and their effects on promoter expression (9E,11E-, 9Z,11E-, or 
10E,12Z-CLA). Although all three isoforms caused a significant decrease in virulence gene 
expression, each did not do so to the same extent. Of the three isoforms, 9Z,11E-CLA was the 
most effective at reducing expression and slightly more effective than the CLA mixture but this 
was not statistically significant. 9E,11E-CLA affected promoter expression the least. Therefore, 
the different isoforms of CLA do not all affect the PtcpA to the same extent. 
ToxT binding activity is reduced in the presence of CLA. Previously we showed that 
linoleic acid was able to directly affect ToxT-binding to DNA, by using EMSA (Chapter One).  
Here, we used this same technique to determine if CLA also affected ToxT-binding to DNA. We 
also used this information to get the ToxT binding curve and the equilibrium constant, Kd. We 
again used the PtcpA as our DNA probe labeled with 
32P while adding increasing amounts of 
purified MBP-ToxT to binding reactions. To each reaction we added DMSO to act as our solvent 
control (Figure 17A, lanes 1-7) or 32 μM CLA dissolved in DMSO (Figure 17A, lanes 8-14) and 
brought the binding reactions to equilibrium for 30 minutes.  These reactions were then run on 
a 6% polyacrylamide gel, followed by autoradiography and analysis using ImageJ software.  
Densitometry analysis was used to calculate the percent bound MBP-ToxT of each 
concentration and then put into GraphPad to get a binding curve as previously described 
(Chapter one). The Kd with no CLA was 5.724nM and the Kd with CLA was 32.07nM. These 
values are significantly different from each other (Figure 17B). 
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Assessment of in vivo effects of CLA on virulence factor production. The results 
described so far indicate that CLA has a strong negative effect on ToxT activity in vitro, as 
assessed by both gene expression (CT production and PtcpA activity) and DNA binding (EMSA). 
The next step was to determine whether administration of CLA in animal models for cholera 
would reduce virulence factor production, leading to decreased colonization and/or fluid 
accumulation induced by CT. The two most common animal models for cholera are the 3-5 day 
old infant mouse model and the adult rabbit ileal loop model. The former is an excellent model 
for assessing colonization, but does not produce a disease state in the mice. The latter is an 
excellent model for assessing CT production, which is exhibited by fluid accumulation in the 
ileal loops. Both models were used to determine whether CLA could reduce V. cholerae 
colonization and/or CT production. 
First, V. cholerae colonization was assessed using the infant mouse model. Because 
infant mouse colonization requires TCP production, this would generally assess whether CLA 
inhibits TCP production in vivo. Mice were infected with classical biotype V. cholerae strain 
O395 or an isogenic toxT deletion strain as a negative control. Groups of mice infected with 
wild-type O395 were either given PBS as a control or CLA at the time of infection, then boosted 
with the appropriate reagent at 3 hours and 6 hours post-infection. 
The results of these experiments are shown in Figure 18. CLA did not cause a significant 
decrease in colonization levels in infant mice. However, there were numerous problems with 
using this model. First, the inoculum was limited to 50 l, due to the size of the mouse pups. 
CLA is also very viscous and difficult to pipet, which required that it be dissolved in a non-
aqueous carrier that could then be emulsified in PBS for administration. This severely limited 
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the amount of CLA that could be administered to the mouse pups. Therefore, although this is a 
negative result, it may not be a good indicator of whether CLA would actually work in vivo in 
the human gut.  
 Second, CT production was assessed using the rabbit ileal loop model. In this case, a 
larger inoculum of 1 ml was used in each loop, which made administration of CLA much easier. 
CLA was either dissolved in ethanol and then suspended in PBS or dissolved in sterile corn oil, 
which is used in vaccine preparations. Preliminary results indicated that ethanol alone inhibited 
CT production, probably due to its toxic effects on the bacteria, so this was excluded from later 
experiments. El Tor strain C6707 was used in these experiments due to its stronger similarity to 
currently circulating disease strains. Figure 19 show the results of a representative ileal loop 
experiments. The administration of CLA, by separate injection, at the time of bacterial 
inoculation resulted approximately three-fold lower fluid volumes that when wild-type C6706 
was injected without CLA (Figure 19A). CT ELISA indicated that the CT levels were also reduced 
when CLA was administered (Figure 19B). By combining the data from these two observations, 
the overall outcome of these experiments was that the total amount of CT produced per loop 
was approximately six-fold lower when CLA was administered (Figure 19C). While this was not 
as strong of an effect as having toxT deleted (Figure 19A), it did strongly suggest that 
administration of CLA in vivo could significantly reduce CT production, which could have an 
effect on the duration and intensity of disease. 
DISCUSSION 
 Because of our findings that linoleic acid has such a strong inhibitory effect of ToxT 
activity, using the related compound conjugated linoleic acid (CLA) as a prophylactic or 
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therapeutic after exposure to V. cholerae became a possibility. There is a strong negative effect 
of CLA on virulence gene expression as shown by both PtcpA activity and CT expression, as well 
as a decrease in ToxT binding to its toxboxes sites on the PtcpA (EMSA). Different isoforms of CLA 
showed some minor differences in effect but no major differences, making CLA production 
easier as currently available mixtures could be used in over-the-counter therapies. 
 Although the infant mouse model showed no reduction in colonization, the model was 
slightly flawed as potentially we could not add a high enough CLA concentration to reduce 
virulence gene expression. This also only looked at O395 classical biotype, and it is possible that 
with El Tor, the more common biotype in the environment, would give different results. The 
duration of colonization could not be determined, and it is possible CLA could reduce its length. 
These are preliminary data, and more troubleshooting could lead to better and more complete 
results. Potentially even using a better solvent for CLA would help. The rabbit ileal loop model, 
showed great promise, however, as CT production was greatly reduced, showing that although 
CLA does not reduce colonization, it may reduce symptoms. Although these results are 
preliminary, the use of CLA with V. cholerae shows promise in reduction of disease. Future 
research will determine whether this will be a feasible and effective addition to current 
rehydration therapy. 
 All in vitro experiments were performed by me, but the in vivo work was done by our 
collaborators in India through NICED with Hemanta Koley, Ph.D. 
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FIGURE 15. Cultures grown under inducing-conditions in the presence of CLA have 
downregulated virulence gene expression. (A) Looking at tcpA::lacZ activation by ToxT by β-
galactosidase assay showed significant downregulation of promoter activity upon the addition 
of 128μM CLA. (B) CT expression was downregulated in the presence of CLA. Statistical 
significance determined using Student’s t-test, *(p<.0001). 
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FIGURE 16. The different isoforms of CLA do not all affect PtcpA to the same extent. V. cholerae 
was grown under virulence-inducing conditions with different isoforms of CLA present and β-
galactosidase assays performed to look at promoter activity. Statistical significance determined 
using Student’s t-test compared to alone (DMSO only) *,p<.05; **,p<.005; ***,p<.0005. 
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FIGURE 17. MBP-ToxT binding to PtcpA DNA was negatively affected in the presence of CLA. (A) 
Autoradiograph of MBP-ToxT binding reactions with PtcpA DNA. Lanes 1-7 have DMSO and lanes 
8-14 have 32µM CLA. (B) Binding curve using densitometry of (A) and GraphPad software show 
significant reduction in the ability of ToxT to bind DNA. Autoradiographs of EMSAs presented 
are representative of three or more independent experiments. The Kd is inset with significant 
difference between the best-fit values denoted by * (p< 0.0001). 
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FIGURE 18. Infant mouse colonization assays. Each symbol represents the data from one 
mouse. CLA was administered using either Kolliphor RH-40 (Kr) or Kollidon 25 (Kn) as a carrier. 
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FIGURE 19. Rabbit ileal loop assays to assess the effect of CLA on fluid accumulation and CT 
production. (A) Ileal loop fluid volumes 16 hours after injection with the indicated mixture. (B) 
CT ELISA indicated CT levels in ileal loop fluid. C) Total CT production in loops containing the 
indicated inoculum.   
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CHAPTER FOUR 
Identifying genes involved in the response to bile in Vibrio cholerae using fluorescence-
activated cell sorting 
Abstract 
Vibrio cholerae causes the severe diarrheal illness cholera. Previous studies have shown 
that bile and its unsaturated fatty acid (UFA) components reduce virulence gene expression. 
The mechanism for the bile-mediated reduction of toxin co-regulated pilus and cholera toxin 
expression through the inhibition of ToxT activity has been described in earlier chapters of this 
dissertation, but it is thought that there are also other genes involved in the direct response to 
bile.  To further characterize the mechanisms for bile inhibition of virulence gene expression, 
we used transposon mutagenesis to make a V. cholerae mutant library containing gene 
knockouts throughout the genome.  Using fluorescence activated cell sorting methods, we 
screened and sorted the mutants using a virulence gene promoter (tcpA) fused to the gene 
encoding green fluorescent protein (gfp) to look for mutants that no longer caused a 
downregulation of tcpA promoter expression in the presence of bile or UFA.  This method has 
resulted in identification of multiple mutants with insertions in pckA, which causes lowered 
sensitivity to bile when mutated or deleted. PckA is known to be involved in the citric acid cycle 
but potentially has another role in virulence. Identifying and characterizing the genes involved 
in the response to bile/UFAs will give us a clearer understanding of the regulatory networks 
controlling virulence gene expression. 
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INTRODUCTION 
V. cholerae is the causative agent of the severe diarrheal disease cholera. Cholera is 
characterized by voluminous diarrhea. In order to initiate disease, production of two virulence 
factors is necessary: cholera toxin (CT) and toxin co-regulated pilus (TCP) both dependent on 
the major transcriptional protein activator ToxT. In the environment, V. cholerae expresses 
motility genes which encode a single, polar flagellum that is used to penetrate the mucus layer 
of the small intestine where V. cholerae then colonizes on the surface of epithelial cells (40). 
Upon finding a site for colonization, the bacteria then downregulate motility gene expression 
and upregulate virulence gene expression (40, 41).  At the site for colonization, many host 
chemicals are present, but two, bile and bicarbonate, have been identified as a negative and 
positive effectors of ToxT, respectively (160, 202-205). 
Bile is secreted by the gall bladder and is a heterogeneous mixture of many different 
components including bile salts, saturated and unsaturated fatty acids, cholesterol, proteins, 
and phospholipids. Bile normally acts as a fat emulsifier and bactericide, but V. cholerae uses it 
as a chemical signal. When added in vitro, bile is shown to cause decreased production of TCP 
and CT, and increased motility, biofilm formation, and outer membrane protein quantities (203-
205).   
To identify genes important for the response to bile, we made a transposon mutant 
library to look for mutants that were insensitive to the effect of bile. This was done by using the 
promoter of tcpA fused to gfp, such that when virulence gene expression is induced by ToxT, 
GFP is produced and can then be used as the marker for virulence gene induction. With GFP as 
our marker, we used fluorescence activated cell sorting (FACS), which has been previously 
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established as a method to isolate bacteria of interest from liquid cultures (230). Using this 
technology we looked for mutants grown in liquid culture that no longer downregulated 
virulence gene expression in response to bile and therefore were expressing high levels of GFP. 
By using FACS, we were able to collect these mutants for further identification and 
characterization. In doing so, we found several genes whose disruption was correlated with a 
decrease in sensitivity to bile, but a gene involved in the citric acid cycle, pckA, was the most 
common. Isolating mutants of V. cholerae that are no longer sensitive to bile allows us to 
identify genes that are involved in the bile response and gives us greater insight into how 
environmental signals affect virulence. 
MATERIALS AND METHODS 
V. cholerae strains and growth conditions. All V. cholerae strains used in the study are 
from classical biotype O395 and this strain was also used to construct the transposon mutant 
library.  Strains and transposon mutants were maintained in Luria Broth (LB) containing 20% 
glycerol and stored at -70°C. A PtcpA::gfp fusion used for flow cytometry was made on pTL61T 
and PtcpA::lacZ used for β-galactosidase assays was inserted into the chromosome using pKAS32 
and conjugation.  Overnight cultures were grown overnight at 37°C in LB and then diluted 1:40 
into LB pH 6.5 at 30°C for virulence inducing conditions in the presence or absence of freshly 
prepared .05% bile (sodium choleate) or 160µM linoleic acid. V. cholerae strains were grown 
with antibiotic concentrations: streptomycin at 100µg/mL, ampicillin at 100µg/mL, and 
kanamycin at 50µg/mL. A deletion of the discovered bile insensitive mutant in pckA was made 
as previously described in a PtcpA::lacZ chromosomal fusion in V. cholerae O395 classical to 
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characterize (220). This strain containing pckA in pBAD33 was also made as a complement to 
express in trans. Deletions of phosphoenolpyruvate carboxylase and isocitrate dehydrogenase 
were also made and put into V. cholerae with a PtcpA::lacZ chromosomal fusion.  
Transposon mutagenesis. Previously a transposon library had been made using the 
suicide plasmid pFD1 in our lab (230). Here we followed the same procedure. Briefly, V. 
cholerae was co-incubated with SM10 (λpir) in E. coli on nitrocellulose filter paper for three 
hours at 37°C. Cells were added to media with streptomycin, ampicillin and 2 mM IPTG to 
induce transposase expression. Bacteria were grown overnight and then transposon mutants 
were selected on LB plates with streptomycin, ampicillin and kanamycin. Plates were incubated 
for 7 hours at 37° C to allow for sufficient colony formation. Colonies were then collected and 
cultured in LB under inducing conditions with 0.5% sodium choleate (bile) or 160 µM linoleic 
acid. Bacteria alone were also cultured as a control. Collected mutants were directly sequenced 
using genomic DNA and primers that bind near the ends of the transposon: BP30 (5′-
ATGCATTTAATACTAGCGACGCC-3′) or BP 31 (5′-CGCTCTTGAAGGGAACTATGTTG-3′). 
Flow cytometry and FACS. As previously described (230), V. cholerae classical strain 
O395 and an otherwise isogenic strain containing a PtcpA::gfp chromosomal fusion were grown 
under virulence-inducing conditions for 3 hours in the presence or absence of bile or linoleic 
acid. V. cholerae lacking the gfp fusion was grown in the absence of effector to set the 
parameter channels of the flow cytometer and the cell sorter in the three parameters; forward 
scatter (FSC), sideward scatter (SSC) and green fluorescence (515–545 nm), using a logarithmic 
scale. For flow cytometry analysis, the expression of gfp was measured by using a FACSscan 
flow cytometer (Becton Dickinson) and the data were further analyzed with FlowJo analysis 
92 
 
 
 
software. For bacterial sorting, high GFP-expressing mutants were sorted using a FACS Diva 
(Becton Dickinson) into LB media and plated to save individual colonies on LB plates with 
ampicillin, streptomycin and kanamycin.  
β-galactosidase assays and CT ELISA. β-galactosidase activity was measured using the 
basic procedure of Miller to confirm mutants were insensitive to bile (212). CT was detected in 
the culture supernatant by a GM1 enzyme-linked immunosorbent assay (ELISA) (228), using 
polyclonal anti-CT antibody (Sigma). All strains and mutants tested were grown under virulence-
inducing conditions for three hours with and without bile and compared. 
RESULTS AND DISCUSSION 
PtcpA::gfp shows decreased expression in the presence of bile or linoleic acid. To look at 
the effect of bile on virulence gene expression, we used a previously constructed gfp plasmid 
fusion that contains the promoter of tcpA. TCP is one of the major virulence factors necessary 
for host colonization and therefore is a useful indicator of virulence gene expression. As an 
experiment for proof-of-concept, we began by looking at the effect of bile or one of its 
unsaturated fatty acid components, linoleic acid, on PtcpA expression using flow cytometry 
(Figures 20A,B). After growing the bacteria under virulence-inducing conditions either alone or 
in the presence of one of the effectors, we measured GFP expression. Without bile or linoleic 
acid, there were high levels of GFP expressed, but upon the addition of either of the negative 
effectors, GFP levels were low. Figure 20B also shows that, at a concentration as low as 16 µM, 
linoleic acid still has an effect on tcpA, but at a concentration lower than that, virulence 
expression is unaffected. These data indicate that GFP levels are high under virulence-inducing 
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conditions, and low upon the addition of negative effectors, indicating this will be a useful 
screening system for use with FACS collection and analysis. 
Collection of V. cholerae mutants potentially insensitive to bile by FACS. The general 
strategy to collect bile insensitive mutants is shown in Figure 21A. We began by creating a 
mariner-based transposon mutant library in V. cholerae O395 that carried chromosomal 
PtcpA::gfp. To identify mutants that had lower sensitivity to bile, and therefore had high GFP 
expression in the presence of bile (Figure 21C), we grew the mutant pool in the presence of bile 
and selected for the highest expressing GFP producers (Figure 21D). We then took this pool, 
grew the bacteria overnight in LB alone to allow recovery, and then subjected the pooled 
mutants to bile treatment again under virulence-inducing conditions, hoping to enrich for the 
mutants that were the least sensitive to effects of bile and thus had the highest GFP levels 
(Figure 21E). On the second day of sorting, there were more mutants expressing high levels of 
GFP, and these mutants were collected for further characterization. 
pckA was identified as the most common mutant in the screen. After FACS analysis, 
mutants were characterized by β-galactosidase assay to ensure that the transposon insertion 
was not present in the PtcpA::gfp construct to somehow cause constitutive activation of GFP. 
Each mutant was tested individually to look at bile sensitivity. The most common disrupted 
gene found in the screen was pckA, encoding phosphoenolpyruvate carboxykinase, an enzyme 
involved in central metabolism that converts oxaloacetate into phosphoenolpyruvate. Another 
gene involved in cell envelope biosynthesis was identified as well, D-alanyl-D-alanine 
carboxypeptidase, but was not studied further. 
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Although the high number of individual pckA mutations recovered from the screen was 
initially promising and suggested a key role for pckA in virulence, ΔpckA strains quickly reverted 
back to wild-type levels of virulence activity, making it very difficult to characterize them 
further. Compared to wild-type, ΔpckA showed only a slight decrease in bile sensitivity in both 
β-galactosidase assays and cholera toxin ELISAs (Figures 22A,B,C). In fact, in the absence of bile, 
ΔpckA actually made more cholera toxin when grown under inducing conditions. It is certainly 
possible, if not probable, that the ΔpckA strain acquired a secondary mutation that 
compensated for the deletion and increased bacterial fitness, as we suspect was rapidly 
happening with the pckA transposon insertion mutants. In spite of this, we examined other 
genes involved in the citric acid cycle to determine whether central metabolism may play a role 
in virulence gene expression levels (Figure 22C). Phosphoenolpyruvate carboxylase, which 
converts phosphoenolpyruvate into oxaloacetate, is an enzyme that works in the opposite 
direction of PckA, and, when deleted, showed no difference in virulence gene expression 
compared to wild-type (Figures 22D,E). Isocitrate dehydrogenase, which works at the rate-
limiting step of the citric acid cycle to convert isocitrate into α-ketoglutarate, also showed no 
effect on virulence expression when deleted (Figures 22D,E). That said, more recent evidence 
suggests that metabolic proteins may have multiple functions and therefore act as 
“moonlighting proteins” (231). These proteins are generally highly conserved (232, 233). 
Although pckA has not yet been discovered to have multiple roles aside from metabolism, the 
possibility is there. The fact that the ΔpckA strain very quickly reverted back to wild-type 
virulence gene expression levels demonstrates the importance of this gene to bacterial fitness. 
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Even though the insensitivity of bile was a modest effect, at only a 10% difference from wild-
type (Figure 3B), the possibility is there that pckA may have a small role in virulence regulation.  
FACS is a useful technique that could be used in other liquid-based screens to identify 
genes involved in other types of effectors or conditions. As only the highest expressing GFP 
mutants were collected, it may be more useful in future work to collect other mutants that 
were expressing GFP levels more comparable to bacteria grown without bile.    
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FIGURE 20. Flow cytometry of negative effectors on virulence expression. Classical biotype 
O395 V. cholerae was grown under virulence-inducing conditions. All histograms show the level 
of gfp fluorescence intensity with a tcpA::gfp fusion plasmid. Cells alone have no gfp reporter 
plasmid and are used to gate proper cell size and as a negative control (A) V. cholerae grown 
with or without the presence of .05% bile. (B) V. cholerae  (B) V. cholerae grown with various 
dilutions of linoleic acid. 
  
a) b) 
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FIGURE 21. Collecting bile insensitive mutants using FACS (A) A general strategy for developing 
a transposon mutant library for identifying genes involved in response to bile. (B)-(D) FACS 
analysis of V. cholerae (B)V. cholerae grown without gfp as a size control (C)  V. cholerae grown under 
virulence-inducing conditions without bile with high expression of PtcpA::gfp. (D) A range 
of gfp expressing mutants was produced when grown under inducing conditions. Most of the mutants 
produce low fluorescence while some produced high gfp. (E) After overnight enrichment of high gfp 
expressing mutants, most mutants express high levels of gfp 
 
  
  
a) 
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FIGURE 22. Characterization of pckA involvement in virulence regulation. (A) V. cholerae was 
grown under virulence-inducing conditions. β-galactosidase assay with and without .05% bile. 
WT – wild-type, pckAΔpckA is deletion strain with a pckA complement in pBAD33 (B) Data 
expressed as a percent of activity between bile compared to no bile for WT and ΔpckA (C) CT 
expression with and without .05% bile from the supernatant of V. cholerae grown under 
virulence-inducing conditions (D) Citric acid cycle and location of deleted genes (E) Other 
metabolism genes deleted and grown under virulence-inducing conditions with and without 
.05% bile. PEPCase – phosphoenolpyruvate carboxylase, IDH – isocitrate dehydrogenase. 
Statistical significance determined using Student’s t-test (*, p<.05; **, p<.005; ***,p<.0005).  
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CONCLUSIONS  
 Vibrio cholerae virulence gene expression is controlled by a complex regulatory cascade 
with its master gene regulator ToxT. ToxT directly activates the promoters of the two major 
virulence factors, cholera toxin (CT) and toxin-coregulated pilus (TCP). When V. cholerae 
colonizes the small intestine, it is able to use environmental signals produced by the host to 
regulate its gene expression. These environmental effectors include the positive effector, 
bicarbonate, as well as the negative effector bile, partially composed of unsaturated fatty acids 
(UFAs) that are thought to be directly responsible. This study has been aimed at elucidating the 
mechanism by which bile and its unsaturated fatty acid components act to downregulate 
virulence. 
 Here, we show that bile and UFAs decrease virulence gene expression. Linoleic acid, 
specifically, is able to enter the cell, where it can then act on ToxT in the cytoplasm. These 
negative effectors act directly on ToxT, causing decreased binding affinity of ToxT for the 
promoters of virulence genes including acfA, acfD, aldA, tagA, tcpA, and tcpI. As most 
promoters have two ToxT binding sites, it has been hypothesized that ToxT acts as a dimer and 
UFAs decrease the ability of ToxT to dimerize. However, aldA only has one ToxT binding site, 
and the observations that aldA gene expression was downregulated and the ability of ToxT to 
bind to the aldA promoter was inhibited by linoleic acid suggest a mechanism by which UFAs 
affect monomeric ToxT. As the data showed, aldA activity was substantially lower than the two 
ToxT-binding site promoters, suggesting that ToxT dimers activate better, but ToxT monomers 
can still activate gene expression. Interestingly, in RNAseq experiments, aldA was the gene 
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whose expression was most highly upregulated in the presence of bicarbonate, the positive 
ToxT effector (data not shown).  
 The unstructured region of ToxT, found when ToxT was crystalized, was mutated to look 
at the effect of bile and UFAs on ToxT itself. We found mutations that were involved in 
response to bile and UFAs. The activity of one mutant in particular, N106F, was not affected by 
the addition of bile or UFAs in terms of virulence gene expression as well as ToxT EMSAs. We 
hypothesize that the large phenylalanine residue may mimic the conformation of ToxT when 
bicarbonate is bound, and therefore, bile and UFAs no longer have an effect. 
 Conjugated linoleic acid (CLA) was studied for a potential use as a prophylactic or 
therapeutic. In vitro CLA downregulates virulence gene expression substantially. Using the 
infant mouse model, CLA had no effect on V. cholerae colonization. However, there were 
significant problems with using this particular animal model for these experiments. Rabbit ileal 
loop assays indicated that both fluid volume and CT concentration were lowered in the 
presence of CLA, suggesting that CLA may be effective as a therapeutic to reduce disease 
symptoms. Further work will be necessary to explore this possibility. 
 Last, a transposon mutant library for use in fluorescence activated cell sorting (FACS) 
genetic screening identified an insertion in pckA, a gene important in metabolism. The pckA 
mutant showed higher expression levels of PtcpA-gfp in the presence of bile. Further studies 
showed that a pckA deletion mutant was only slightly less sensitive to bile, but this does 
suggest that genes important in metabolism can have effects on virulence gene expression. 
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Future Directions 
Although much work has been done to determine the mechanism by which UFAs 
downregulate virulence, there is still much work that can be done. To begin, it would be useful 
to use the two-hybrid bacterial system to look at linoleic acid’s effect on dimerization. Although 
our data suggest it is not dimerization by which linoleic acid decreases ToxT DNA binding 
affinity, this would add further confirmation. Although not discussed in this dissertation, 
surface plasmon resonance (SPR) was explored to identify binding changes upon addition of 
linoleic acid. Further exploration of this technique could give real-time data of the binding 
patterns of ToxT in response to linoleic acid, and potentially, the heterogeneous mixture of bile. 
This could include using the ToxT mutations in the unstructured region and comparing binding 
patterns as well. Also, the interplay of linoleic acid and the positive effector bicarbonate is 
something that could be further explored either through more EMSAs or SPR. Adding an 
additional toxbox to the aldA promoter or removing one from a promoter with two toxboxes 
may give some more useful information on the regulation of the effectors. Also, we could use 
human epithelial cells and add exogenous bile and/or bicarbonate to study surface colonization 
that could give greater understanding to how these effectors may act in the host. 
The CLA aspect of this project shows a substantial negative effect of CLA in vitro. 
Experiments with rabbit ileal loops also indicated that CLA reduced CT production in vivo. The 
use of CLA as a prophylactic or therapeutic could be useful, but much work still needs to be 
done including identifying the right concentrations of CLA to use.  
Characterization of the other genes identified in the FACS screen would also be useful. 
Potentially there is a transport mechanism that imports UFAs into the cell, and discovery of 
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genes responsible for this would further our knowledge of a location in which other negative 
effectors (therapeutics) could target to reduce disease in humans.  
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 Vibrio cholerae is responsible for the diarrheal disease cholera by producing two major 
virulence factors: cholera toxin (CT) and toxin-coregulated pilus (TCP). During infection, V. 
cholerae downregulates its motility genes, which are actively expressed in the environment, 
and upregulates its virulence genes, which are inactive in the environment. Virulence gene 
transcription is regulated by the major transcriptional activator, ToxT. ToxT is regulated, in part, 
by host signals, which in turn, make ToxT active or inactive in respect to virulence gene 
expression. Host signals include temperature and pH as well as the chemical molecules 
bicarbonate and bile, which are positive and negative effectors of virulence, respectively. Bile is 
a heterogeneous mixture that includes unsaturated fatty acids (UFAs) that have been directly 
implicated in virulence gene downregulation. Another small molecule, virstatin, has also been 
shown to cause virulence gene downregulation. This dissertation focuses on the mechanism by 
which bile and its UFA components, specifically linoleic acid, downregulate virulence gene 
expression. 
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The first chapter focuses on the decreased binding affinity of ToxT for various virulence 
gene promoters at the ToxT binding sites, termed toxboxes. These toxboxes come in different 
configurations and orientations, and while most promoters have two toxboxes, aldA only has 
one. I showed that linoleic acid can enter the cell where it can go into the cytoplasm and then 
interact with ToxT. It has been hypothesized that UFAs cause decreased dimerization; however 
at PaldA, linoleic acid still had an effect. Virstatin, which has been shown directly to decrease 
dimerization of ToxT, did not have an effect on ToxT DNA binding at PaldA. This suggests a 
mechanism in which UFAs do not affect dimerization but can affect monomeric ToxT binding to 
DNA.   
In chapter two, we characterize an unstructured region of the N-terminal domain of 
ToxT in response to bile and UFAs. By mutating each of the 10 amino acids in the region, we 
discovered a mutant, N106F, which had decreased response to bile and UFAs. It also showed 
decreased response to the positive regulator bicarbonate.  
Chapter three discusses the possibility of using conjugated linoleic acid (CLA) as a 
therapeutic or prophylactic upon exposure to V. cholerae. The in vitro work showed a strong 
decrease of ToxT activity in response to CLA on both gene expression and DNA binding. In the 
infant mouse model, CLA did not inhibit colonization, but in the rabbit ileal loop model CT 
production was significantly decreased, suggesting that CLA may work to reduce cholera 
symptoms. 
In the last chapter, we looked at the possibility of using fluorescence-activated cell 
screening (FACS) in addition to transposon mutagenesis as a method to collect mutants that 
were insensitive to bile. Use of this technique would allow us to discover genes that were 
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directly responsible for the effects of bile. Several genes were identified, including pckA, which 
is involved in metabolism, but could have a role in virulence. When deleted, however, the 
bacteria were only slightly less sensitive to bile than wild-type. FACS genetic screening is still a 
useful technique that, if further explored, could elucidate other genes involved in responding to 
effectors of virulence.  
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